The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
3',4',7-trihydroxyisoflavone results in decreased expression of ABCB1 mRNA 3',4',7-trihydroxyisoflavone inhibits the reaction [Epirubicin results in increased expression of ABCB1 mRNA]; Acetylcysteine inhibits the reaction [3',4',7-trihydroxyisoflavone results in decreased expression of ABCB1 mRNA]; Ascorbic Acid inhibits the reaction [3',4',7-trihydroxyisoflavone results in decreased expression of ABCB1 mRNA]; CAT protein inhibits the reaction [3',4',7-trihydroxyisoflavone results in decreased expression of ABCB1 mRNA]
3',4',7-trihydroxyisoflavone inhibits the reaction [Epirubicin results in increased expression of ABCC1 mRNA]; Acetylcysteine inhibits the reaction [3',4',7-trihydroxyisoflavone results in decreased expression of ABCC1 mRNA]; Ascorbic Acid inhibits the reaction [3',4',7-trihydroxyisoflavone results in decreased expression of ABCC1 mRNA]; CAT protein inhibits the reaction [3',4',7-trihydroxyisoflavone results in decreased expression of ABCC1 mRNA]
3',4',7-trihydroxyisoflavone inhibits the reaction [Epirubicin results in increased expression of ABCC2 mRNA]; Acetylcysteine inhibits the reaction [3',4',7-trihydroxyisoflavone results in decreased expression of ABCC2 mRNA]; Ascorbic Acid inhibits the reaction [3',4',7-trihydroxyisoflavone results in decreased expression of ABCC2 mRNA]; CAT protein inhibits the reaction [3',4',7-trihydroxyisoflavone results in decreased expression of ABCC2 mRNA]
3',4',7-trihydroxyisoflavone results in increased expression of BAX mRNA 3',4',7-trihydroxyisoflavone promotes the reaction [Epirubicin results in increased expression of BAX mRNA]; Epirubicin promotes the reaction [3',4',7-trihydroxyisoflavone results in increased expression of BAX mRNA]
3',4',7-trihydroxyisoflavone promotes the reaction [Epirubicin results in increased expression of CASP3 mRNA]; Epirubicin promotes the reaction [3',4',7-trihydroxyisoflavone results in increased activity of CASP3 protein]; Epirubicin promotes the reaction [3',4',7-trihydroxyisoflavone results in increased expression of CASP3 mRNA]
3',4',7-trihydroxyisoflavone promotes the reaction [Epirubicin results in increased expression of CASP9 mRNA]; Epirubicin promotes the reaction [3',4',7-trihydroxyisoflavone results in increased activity of CASP9 protein]; Epirubicin promotes the reaction [3',4',7-trihydroxyisoflavone results in increased expression of CASP9 mRNA]
CAT protein inhibits the reaction [3',4',7-trihydroxyisoflavone results in decreased expression of ABCB1 mRNA]; CAT protein inhibits the reaction [3',4',7-trihydroxyisoflavone results in decreased expression of ABCC1 mRNA]; CAT protein inhibits the reaction [3',4',7-trihydroxyisoflavone results in decreased expression of ABCC2 mRNA]
3',4',7-trihydroxyisoflavone promotes the reaction [Epirubicin results in increased expression of TP53 mRNA]; Epirubicin promotes the reaction [3',4',7-trihydroxyisoflavone results in increased expression of TP53 mRNA]
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of AVP protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate results in increased secretion of AVP protein]
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]]
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [NOX1 protein promotes the reaction [glycylphenylalanine 2-naphthylamide results in increased export of Calcium]]
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of OXT protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate results in increased secretion of OXT protein]
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX7 protein] pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein]
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]]
Alpha-Amanitin results in decreased expression of BCL2 protein 3-methyladenine inhibits the reaction [Alpha-Amanitin results in decreased expression of BCL2 protein]
3-methyladenine inhibits the reaction [Alpha-Amanitin results in increased expression of BECN1 protein]; Alpha-Amanitin inhibits the reaction [dorsomorphin results in decreased expression of BECN1 protein]
Alpha-Amanitin results in increased cleavage of CASP3 protein 3-methyladenine inhibits the reaction [Alpha-Amanitin results in increased cleavage of CASP3 protein]; Sirolimus promotes the reaction [Alpha-Amanitin results in increased cleavage of CASP3 protein]
Alpha-Amanitin results in increased expression of GPT protein [Polymyxin B co-treated with Methylprednisolone] inhibits the reaction [Alpha-Amanitin results in increased expression of GPT protein]; Methylprednisolone inhibits the reaction [Alpha-Amanitin results in increased expression of GPT protein]; Polymyxin B inhibits the reaction [Alpha-Amanitin results in increased expression of GPT protein]
Alpha-Amanitin results in increased expression of and results in increased lipidation of MAP1LC3B protein Alpha-Amanitin affects the lipidation of MAP1LC3B protein 3-methyladenine affects the reaction [Alpha-Amanitin affects the lipidation of MAP1LC3B protein]; Alpha-Amanitin inhibits the reaction [dorsomorphin results in decreased lipidation of MAP1LC3B protein]
Alpha-Amanitin results in increased activity of MPO protein [Polymyxin B co-treated with Methylprednisolone] inhibits the reaction [Alpha-Amanitin results in increased activity of MPO protein]; Methylprednisolone inhibits the reaction [Alpha-Amanitin results in increased activity of MPO protein]; Polymyxin B inhibits the reaction [Alpha-Amanitin results in increased activity of MPO protein]
Alpha-Amanitin results in decreased expression of and results in decreased phosphorylation of MTOR protein Alpha-Amanitin results in decreased expression of and results in decreased phosphorylation of MTOR protein; Sirolimus promotes the reaction [Alpha-Amanitin results in decreased expression of and results in decreased phosphorylation of MTOR protein] Alpha-Amanitin inhibits the reaction [dorsomorphin results in increased expression of and results in increased phosphorylation of MTOR protein]
Alpha-Amanitin results in increased degradation of POLR2A protein Alpha-Amanitin results in increased expression of POLR2A mRNA; Alpha-Amanitin results in increased expression of POLR2A protein
Alpha-Amanitin results in increased expression of ULK1 protein Alpha-Amanitin inhibits the reaction [3-methyladenine results in decreased expression of ULK1 protein]; Alpha-Amanitin inhibits the reaction [dorsomorphin results in decreased expression of ULK1 protein]; Sirolimus promotes the reaction [Alpha-Amanitin results in increased expression of ULK1 protein]
[2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one results in decreased activity of ATM protein] inhibits the reaction [Aphidicolin results in increased phosphorylation of TRIM28 protein]; [2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one results in decreased activity of ATM protein] inhibits the reaction [Aphidicolin results in increased phosphorylation of TRP53 protein]
[schizandrin B results in decreased activity of ATR protein] inhibits the reaction [Aphidicolin results in increased expression of BSCL2 mRNA]; [schizandrin B results in decreased activity of ATR protein] inhibits the reaction [Aphidicolin results in increased phosphorylation of CHEK1 protein]; [schizandrin B results in decreased activity of ATR protein] inhibits the reaction [Aphidicolin results in increased phosphorylation of TRP53 protein]
[7-hydroxystaurosporine results in decreased activity of [CHEK1 protein co-treated with BSCL2 protein]] inhibits the reaction [Aphidicolin results in increased expression of CHEK2 mRNA]; [schizandrin B results in decreased activity of ATR protein] inhibits the reaction [Aphidicolin results in increased expression of BSCL2 mRNA]
[7-hydroxystaurosporine results in decreased activity of [CHEK1 protein co-treated with BSCL2 protein]] inhibits the reaction [Aphidicolin results in increased expression of CHEK2 mRNA]; [schizandrin B results in decreased activity of ATR protein] inhibits the reaction [Aphidicolin results in increased phosphorylation of CHEK1 protein]
Caffeine promotes the reaction [Aphidicolin promotes the reaction [PRKDC protein results in increased phosphorylation of and results in increased activity of CHEK2 protein]] [7-hydroxystaurosporine results in decreased activity of [CHEK1 protein co-treated with BSCL2 protein]] inhibits the reaction [Aphidicolin results in increased expression of CHEK2 mRNA]
Caffeine promotes the reaction [Aphidicolin promotes the reaction [PRKDC protein results in increased phosphorylation of and results in increased activity of CHEK2 protein]]
[2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one results in decreased activity of ATM protein] inhibits the reaction [Aphidicolin results in increased phosphorylation of TRP53 protein]; [schizandrin B results in decreased activity of ATR protein] inhibits the reaction [Aphidicolin results in increased phosphorylation of TRP53 protein]
[2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one results in decreased activity of ATM protein] inhibits the reaction [Aphidicolin results in increased phosphorylation of TRIM28 protein]
baicalin results in increased expression of BAX protein baicalin affects the reaction [Rotenone results in increased expression of BAX mRNA]; baicalin inhibits the reaction [Rotenone results in increased expression of BAX protein] baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of BAX mRNA]; baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of BAX protein]; baicalin inhibits the reaction [Gentamicins results in increased expression of BAX mRNA]; baicalin inhibits the reaction [Gentamicins results in increased expression of BAX protein] baicalin inhibits the reaction [Rotenone affects the expression of BAX protein]
baicalin inhibits the reaction [Rotenone affects the expression of BCL2 protein] baicalin results in decreased expression of BCL2 protein baicalin affects the reaction [Rotenone results in decreased expression of BCL2 mRNA]; baicalin inhibits the reaction [Rotenone results in decreased expression of BCL2 protein] baicalin inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 mRNA]; baicalin inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein]; baicalin inhibits the reaction [Gentamicins results in decreased expression of BCL2 mRNA]; baicalin inhibits the reaction [Gentamicins results in decreased expression of BCL2 protein]
baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP1 protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of CASP1 protein]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of CASP1 protein]]
baicalin inhibits the reaction [Rotenone affects the expression of CASP3 protein] baicalin affects the reaction [Rotenone results in decreased activity of CASP3 protein] baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of CASP3 mRNA]; baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of CASP3 protein]; baicalin inhibits the reaction [Gentamicins results in increased cleavage of CASP3 protein]
baicalin results in increased expression of CCND1 mRNA baicalin results in decreased expression of CCND1 protein N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of CCND1 mRNA]
3',4'-dimethoxyflavone inhibits the reaction [baicalin results in increased expression of CYP1A1 mRNA]; 3',4'-dimethoxyflavone inhibits the reaction [baicalin results in increased expression of CYP1A1 protein]; baicalin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] baicalin results in increased expression of CYP1A1 mRNA; baicalin results in increased expression of CYP1A1 protein
3',4'-dimethoxyflavone inhibits the reaction [baicalin results in increased expression of CYP1A2 mRNA]; 3',4'-dimethoxyflavone inhibits the reaction [baicalin results in increased expression of CYP1A2 protein] resveratrol inhibits the reaction [baicalin results in increased expression of CYP1A2 mRNA]; resveratrol inhibits the reaction [baicalin results in increased expression of CYP1A2 protein] baicalin results in increased expression of CYP1A2 mRNA; baicalin results in increased expression of CYP1A2 protein
baicalin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; baicalin inhibits the reaction [EGF protein results in increased phosphorylation of ELK1 protein]
baicalin inhibits the reaction [tert-Butylhydroperoxide results in increased activity of GPT protein] baicalin inhibits the reaction [Arsenic Trioxide results in increased activity of GPT protein]
baicalin results in increased expression of HES1 mRNA N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of HES1 mRNA]
baicalin results in increased expression of HEY1 mRNA N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of HEY1 mRNA]
[baicalin co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of HMOX1 protein; baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HMOX1 protein]; baicalin promotes the reaction [Carbon Tetrachloride results in increased expression of HMOX1 mRNA]; baicalin promotes the reaction [Carbon Tetrachloride results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [[baicalin co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of HMOX1 protein] baicalin results in increased expression of HMOX1 mRNA; baicalin results in increased expression of HMOX1 protein
baicalin inhibits the reaction [HNF4A protein binds to HNF1A promoter]; HNF1A protein promotes the reaction [baicalin results in decreased secretion of Hepatitis B Surface Antigens]; HNF4A protein promotes the reaction [baicalin results in decreased expression of HNF1A mRNA]; HNF4A protein promotes the reaction [baicalin results in decreased expression of HNF1A protein] baicalin results in decreased expression of HNF1A mRNA; baicalin results in decreased expression of HNF1A protein
baicalin results in decreased expression of HNF4A protein baicalin inhibits the reaction [HNF4A protein binds to HNF1A promoter]; HNF4A protein promotes the reaction [baicalin results in decreased expression of HNF1A mRNA]; HNF4A protein promotes the reaction [baicalin results in decreased expression of HNF1A protein]; HNF4A protein promotes the reaction [baicalin results in decreased secretion of Hepatitis B Surface Antigens] baicalin results in decreased expression of HNF4A mRNA; baicalin results in decreased expression of HNF4A protein
baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B mRNA]; baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL1B mRNA]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL1B protein]; baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of IL1B protein]; baicalin inhibits the reaction [Palmitic Acid results in increased secretion of IL1B protein]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL1B protein]] baicalin inhibits the reaction [Rotenone results in increased expression of IL1B protein]
baicalin results in decreased expression of IL6 mRNA; baicalin results in decreased expression of IL6 protein baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL6 mRNA]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL6 mRNA]; baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of IL6 protein]; baicalin inhibits the reaction [Palmitic Acid results in increased secretion of IL6 protein]
baicalin inhibits the reaction [ITGA4 protein results in increased expression of KDR protein]; baicalin inhibits the reaction [ITGA4 protein results in increased expression of VEGFA protein]
baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of KEAP1 protein]; baicalin promotes the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in decreased expression of KEAP1 protein]
[baicalin co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] affects the localization of NFE2L2 protein; baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NFE2L2 protein]; baicalin inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased ubiquitination of NFE2L2 protein]; baicalin promotes the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NFE2L2 protein]; baicalin promotes the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [[baicalin co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of CASP1 protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL1B protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NLRP3 protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of PYCARD protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased phosphorylation of RELA protein]]
baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NLRP3 protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NLRP3 protein]; baicalin inhibits the reaction [Palmitic Acid results in increased expression of NLRP3 protein]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NLRP3 protein]]
baicalin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; baicalin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; mifobate inhibits the reaction [baicalin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]] baicalin results in decreased expression of NOS2 mRNA; baicalin results in decreased expression of NOS2 protein baicalin inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 mRNA]; baicalin inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein]
baicalin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased phosphorylation of and results in decreased activity of PPARG protein]
baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PYCARD protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of PYCARD protein]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of PYCARD protein]]
baicalin affects the localization of and results in decreased expression of RELA protein baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased phosphorylation of RELA protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased phosphorylation of RELA protein]; baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of and results in increased phosphorylation of RELA protein]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased phosphorylation of RELA protein]]
[baicalin co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] affects the localization of NFE2L2 protein; [baicalin co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of HMOX1 protein; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of CASP1 protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL1B mRNA]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL1B protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL6 mRNA]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NLRP3 protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of PYCARD protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of TNF mRNA]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased phosphorylation of RELA protein]; baicalin inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased ubiquitination of NFE2L2 protein]; baicalin promotes the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in decreased expression of KEAP1 protein]; baicalin promotes the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NFE2L2 protein]; baicalin promotes the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [[baicalin co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of CASP1 protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL1B protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NLRP3 protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of PYCARD protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased phosphorylation of RELA protein]]
baicalin inhibits the reaction [Streptozocin results in decreased expression of TGFB1 mRNA]; baicalin inhibits the reaction [TGFB1 protein results in increased expression of COL1A2 mRNA]
baicalin results in decreased expression of TLR4 protein baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of TLR4 protein] baicalin inhibits the reaction [Lipopolysaccharides results in increased expression of TLR4 protein]
baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF mRNA]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of TNF mRNA]; baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of TNF protein]; baicalin inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF mRNA]; baicalin inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein] baicalin results in decreased expression of TNF mRNA; baicalin results in decreased expression of TNF protein baicalin inhibits the reaction [Paraquat results in increased expression of TNF protein]
baicalin inhibits the reaction [Palmitic Acid results in increased expression of TXNIP protein]; dorsomorphin inhibits the reaction [baicalin inhibits the reaction [Palmitic Acid results in increased expression of TXNIP protein]]
corilagin inhibits the reaction [Morphine results in increased expression of AIF1 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of AIF1 protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of AIF1 protein]]
corilagin inhibits the reaction [Doxorubicin results in increased expression of AKT1 protein]; corilagin inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of AKT1 mRNA] corilagin results in decreased expression of AKT1 protein
corilagin inhibits the reaction [Morphine results in increased expression of ATF4 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of ATF4 protein]]
corilagin inhibits the reaction [Doxorubicin results in increased expression of BAX protein]; corilagin inhibits the reaction [Methylnitronitrosoguanidine results in decreased expression of BAX protein]
corilagin inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; corilagin inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of BCL2 protein]
corilagin inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein]; corilagin inhibits the reaction [Methylnitronitrosoguanidine results in decreased expression of CASP3 protein] corilagin inhibits the reaction [Morphine results in increased cleavage of CASP3 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased cleavage of CASP3 protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased cleavage of CASP3 protein]]
corilagin inhibits the reaction [Doxorubicin results in decreased activity of CAT protein]; corilagin inhibits the reaction [Methylnitronitrosoguanidine results in decreased activity of CAT protein]; corilagin inhibits the reaction [Streptozocin results in decreased activity of CAT protein] corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of CAT mRNA]
corilagin inhibits the reaction [Morphine results in increased expression of DDIT3 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of DDIT3 protein]]
corilagin inhibits the reaction [Morphine results in increased phosphorylation of EIF2AK3 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased phosphorylation of EIF2AK3 protein]]
corilagin inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; corilagin inhibits the reaction [TNFSF11 protein results in increased expression of FOS protein]
corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of HMOX1 protein]; tin protoporphyrin IX inhibits the reaction [corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of HMOX1 protein]]
corilagin inhibits the reaction [Morphine results in increased expression of HSPA5 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of HSPA5 protein]]
corilagin inhibits the reaction [Morphine results in increased expression of IL1B protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of IL1B protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of IL1B protein]]
corilagin inhibits the reaction [Doxorubicin results in increased expression of IL6 protein] corilagin inhibits the reaction [Morphine results in increased expression of IL6 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of IL6 protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of IL6 protein]] corilagin results in decreased expression of IL6 protein
corilagin inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; corilagin inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 protein]
corilagin inhibits the reaction [Morphine results in increased expression of NLRP3 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of NLRP3 protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of NLRP3 protein]]
corilagin results in decreased expression of NOS2 protein corilagin inhibits the reaction [Morphine results in increased expression of NOS2 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of NOS2 protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of NOS2 protein]]
corilagin inhibits the reaction [1-naphthyl isothiocyanate decreases expression of nr1h4 mRNA and protein in rat liver]; corilagin increases expression of nr1h4 mRNA and protein in rat embryonic liver cells
corilagin results in decreased expression of PTGS2 protein corilagin inhibits the reaction [Morphine results in increased expression of PTGS2 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of PTGS2 protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of PTGS2 protein]]
corilagin inhibits the reaction [Morphine results in increased expression of PYCARD protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of PYCARD protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of PYCARD protein]]
corilagin inhibits the reaction [Morphine results in increased expression of TLR2 mRNA]; corilagin inhibits the reaction [Morphine results in increased expression of TLR2 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased cleavage of CASP3 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of AIF1 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of ATF4 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of DDIT3 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of HSPA5 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of IL1B protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of IL6 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of NLRP3 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of NOS2 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of PTGS2 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of PYCARD protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of TNF protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased phosphorylation of EIF2AK3 protein]]
corilagin results in decreased secretion of TNF protein corilagin inhibits the reaction [Morphine results in increased expression of TNF protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of TNF protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of TNF protein]] corilagin results in decreased expression of TNF protein corilagin inhibits the reaction [Doxorubicin results in increased expression of TNF protein]
[corilagin co-treated with TNFSF11 protein] results in increased expression of GSR mRNA; corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of CAT mRNA]; corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of HMOX1 protein]; corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of NFE2L2 mRNA]; corilagin inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; corilagin inhibits the reaction [TNFSF11 protein results in increased expression of FOS protein]; corilagin inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; corilagin inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 protein]; tin protoporphyrin IX inhibits the reaction [corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of HMOX1 protein]]
BRCA2 protein affects the susceptibility to CX 5461 BRCA2 protein affects the reaction [CX 5461 results in increased expression of TP53BP1 protein]; BRCA2 protein affects the reaction [CX 5461 results in increased phosphorylation of RPA2 protein]
CX 5461 results in increased phosphorylation of RPA2 protein BRCA2 protein affects the reaction [CX 5461 results in increased phosphorylation of RPA2 protein]
daidzein inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; daidzein promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]
daidzein inhibits the reaction [ABCC5 protein results in decreased susceptibility to Thioguanine]; daidzein inhibits the reaction [ABCC5 protein results in increased export of 2',7'-bis(carboxyethyl)-5(6)-carboxyfluorescein]
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of ACSL3 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of ALDH1A2 mRNA
[daidzein binds to ESR1 protein] which results in increased activity of ALPL protein; fulvestrant inhibits the reaction [[daidzein binds to ESR1 protein] which results in increased activity of ALPL protein]
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of ANPEP mRNA
daidzein promotes the reaction [TGFB1I1 protein results in increased activity of AR protein] daidzein inhibits the reaction [Flutamide results in decreased expression of AR mRNA]; daidzein inhibits the reaction [Flutamide results in decreased expression of AR protein] daidzein results in decreased expression of AR mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of ATOH8 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of BCKDK mRNA
[daidzein co-treated with ESR1 protein] results in increased expression of BGLAP mRNA; [daidzein co-treated with ESR2 protein] results in increased expression of BGLAP mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of BPGM mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CABP5 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of CACYBP mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CASP8AP2 mRNA
[Genistein co-treated with daidzein] inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased activity of CAT protein] daidzein inhibits the reaction [Flutamide results in decreased activity of CAT protein]
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CD200R1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of CFAP251 mRNA
daidzein results in decreased activity of COMT protein daidzein inhibits the reaction [COMT protein results in increased methylation of 4-hydroxyestradiol]; fulvestrant inhibits the reaction [daidzein results in decreased expression of COMT mRNA]
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CYBRD1 mRNA
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of CYP11A1 mRNA
daidzein results in decreased activity of CYP19A1 protein [Genistein co-treated with biochanin A co-treated with daidzein] results in decreased activity of CYP19A1 protein; [Genistein co-treated with biochanin A co-treated with daidzein] results in decreased expression of CYP19A1 mRNA daidzein results in decreased expression of CYP19A1 mRNA
daidzein results in decreased activity of CYP1A1 protein daidzein inhibits the reaction [Omeprazole results in increased expression of CYP1A1 mRNA]; daidzein inhibits the reaction [Omeprazole results in increased expression of CYP1A1 protein] daidzein results in decreased expression of CYP1A1 mRNA daidzein inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; fulvestrant inhibits the reaction [daidzein results in decreased expression of CYP1A1 mRNA]
daidzein results in decreased activity of CYP2E1 protein daidzein inhibits the reaction [[CYP2E1 protein results in increased metabolism of 4-nitrophenol] which results in increased chemical synthesis of 4-nitrocatechol]
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of DENND2D mRNA
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased expression of DNMT1 mRNA
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased expression of DNMT3A mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of DPP9 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of EDRF1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of EFHD1 mRNA
[daidzein co-treated with ESR1 protein] results in decreased expression of EGFR mRNA; [daidzein co-treated with ESR1 protein] results in decreased expression of EGFR protein; [daidzein co-treated with ESR2 protein] results in decreased expression of EGFR mRNA; [daidzein co-treated with ESR2 protein] results in decreased expression of EGFR protein
[daidzein binds to ESR1 protein] which results in increased activity of ALPL protein; [daidzein co-treated with ESR1 protein] results in decreased expression of EGFR mRNA; [daidzein co-treated with ESR1 protein] results in decreased expression of EGFR protein; [daidzein co-treated with ESR1 protein] results in increased expression of BGLAP mRNA; [daidzein co-treated with ESR1 protein] results in increased expression of BSP mRNA; daidzein binds to and results in increased activity of ESR1 protein; daidzein inhibits the reaction [bisphenol A results in decreased expression of ESR1 mRNA]; daidzein inhibits the reaction [Estradiol binds to ESR1 protein]; daidzein metabolite binds to and results in increased activity of ESR1 protein; daidzein metabolite promotes the reaction [NCOA2 protein binds to ESR1 protein]; daidzein promotes the reaction [Estradiol results in increased activity of ESR1 protein]; ESR1 protein affects the reaction [daidzein results in decreased expression of IL6 mRNA]; ESR1 protein affects the reaction [daidzein results in decreased secretion of IL6 protein]; ESR1 protein inhibits the reaction [daidzein results in increased expression of CXCL12 mRNA]; ESR1 protein inhibits the reaction [daidzein results in increased expression of GREB1 mRNA]; ESR1 protein inhibits the reaction [daidzein results in increased expression of PGR mRNA]; ESR1 protein inhibits the reaction [daidzein results in increased expression of PRSS23 mRNA]; ESR1 protein inhibits the reaction [daidzein results in increased expression of TFF1 mRNA]; Estradiol affects the reaction [daidzein metabolite affects the activity of ESR1 protein]; Fulvestrant inhibits the reaction [[daidzein binds to ESR1 protein] which results in increased activity of ALPL protein] daidzein results in increased expression of ESR1 mRNA; daidzein results in increased expression of ESR1 protein daidzein results in increased activity of ESR1 protein ESR1 protein affects the susceptibility to daidzein daidzein results in decreased expression of ESR1 mRNA; daidzein results in decreased expression of ESR1 protein
[daidzein co-treated with ESR2 protein] results in decreased expression of EGFR mRNA; [daidzein co-treated with ESR2 protein] results in decreased expression of EGFR protein; [daidzein co-treated with ESR2 protein] results in increased expression of BGLAP mRNA; [daidzein co-treated with ESR2 protein] results in increased expression of BSP mRNA; [daidzein co-treated with ESR2 protein] results in increased expression of PTGS2 mRNA; daidzein binds to and results in increased activity of ESR2 protein; daidzein inhibits the reaction [Estradiol binds to ESR2 protein]; daidzein inhibits the reaction [KAT5 protein results in increased activity of ESR2 protein]; daidzein metabolite binds to and results in increased activity of ESR2 protein; daidzein promotes the reaction [Estradiol results in increased activity of ESR2 protein]; ESR2 affects the reaction [daidzein results in increased expression of CDKN1A]; ESR2 gene polymorphism affects the reaction [[Genistein co-treated with daidzein] affects the expression of VCAM1 protein]; ESR2 gene polymorphism affects the susceptibility to [Genistein co-treated with daidzein]; Estradiol affects the reaction [daidzein metabolite affects the activity of ESR2 protein] daidzein results in increased expression of ESR2 mRNA; daidzein results in increased expression of ESR2 protein [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased expression of ESR2 mRNA daidzein binds to ESR2 protein ESR2 affects the susceptibility to daidzein daidzein results in increased activity of ESR2 protein daidzein results in increased activity of ESR2 protein; daidzein results in increased activity of ESR2 protein alternative form
daidzein binds to and results in increased activity of ESRRA protein; daidzein binds to and results in increased activity of ESRRA protein mutant form; daidzein promotes the reaction [ESRRA protein binds to PNRC1 protein]
daidzein inhibits the reaction [bisphenol A results in increased expression of ESRRG mRNA]; daidzein inhibits the reaction [bisphenol A results in increased expression of ESRRG protein]; daidzein promotes the reaction [ESRRG protein binds to PNRC1 protein]
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of FAM171A2 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of FAM180A mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of FAM210B mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of FAM241B mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of FGD6 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of FHL2 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of GALNT15 mRNA
daidzein promotes the reaction [GNB1 protein results in increased activity of PLCB2 protein results in increased activity of MAPK1 protein]; daidzein promotes the reaction [GNB1 protein results in increased activity of PLCB2 protein results in increased activity of MAPK3 protein]; daidzein promotes the reaction [GNB1 protein results in increased activity of PLCB2 protein]
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of GNG5 mRNA
daidzein results in increased expression of GREB1 mRNA ESR1 protein inhibits the reaction [daidzein results in increased expression of GREB1 mRNA]; Fulvestrant inhibits the reaction [daidzein results in increased expression of GREB1 mRNA]
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of HIPK4 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of HMCN1 mRNA
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of HSD3B1 mRNA
[daidzein co-treated with ESR1 protein] results in increased expression of BSP mRNA; [daidzein co-treated with ESR2 protein] results in increased expression of BSP mRNA
daidzein inhibits the reaction [Lipopolysaccharides results in increased expression of IL12B mRNA]; daidzein inhibits the reaction [Lipopolysaccharides results in increased expression of IL12B protein]
daidzein inhibits the reaction [IL1B protein results in increased secretion of IL6 protein] [Genistein co-treated with daidzein] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL1B protein]
daidzein inhibits the reaction [IL1B protein results in increased secretion of IL6 protein]; ESR1 protein affects the reaction [daidzein results in decreased expression of IL6 mRNA]; ESR1 protein affects the reaction [daidzein results in decreased secretion of IL6 protein] [Genistein co-treated with daidzein] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL6 protein]; daidzein inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; daidzein inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; daidzein inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of IL6R mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of ISG20L2 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of KDM5A mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of KITLG mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of KNSTRN mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of LDLRAP1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of LMOD1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of LRG1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of LSR mRNA
AG 1879 inhibits the reaction [daidzein results in increased phosphorylation of MAPK1 protein] daidzein promotes the reaction [GNB1 protein results in increased activity of PLCB2 protein results in increased activity of MAPK1 protein]; daidzein results in increased phosphorylation of and results in increased activity of MAPK1 protein
AG 1879 inhibits the reaction [daidzein results in increased phosphorylation of MAPK3 protein] daidzein promotes the reaction [GNB1 protein results in increased activity of PLCB2 protein results in increased activity of MAPK3 protein]; daidzein results in increased phosphorylation of and results in increased activity of MAPK3 protein
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of MRPL33 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of MTMR11 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of MYOF mRNA
[daidzein binds to THRB protein] promotes the reaction [NCOA1 protein binds to THRB protein]; daidzein promotes the reaction [NCOA1 protein binds to THRB protein] daidzein results in increased expression of NCOA1 mRNA; daidzein results in increased expression of NCOA1 protein
daidzein inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; daidzein inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] daidzein results in decreased activity of NOS2 protein
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of NR4A1 mRNA
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of NR5A1 mRNA; [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of NR5A1 protein; [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased methylation of NR5A1 promoter; decitabine inhibits the reaction [[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of NR5A1 mRNA]
daidzein results in increased expression of PGR mRNA; daidzein results in increased expression of PGR protein ESR1 protein inhibits the reaction [daidzein results in increased expression of PGR mRNA]
daidzein promotes the reaction [GNB1 protein results in increased activity of PLCB2 protein results in increased activity of MAPK1 protein]; daidzein promotes the reaction [GNB1 protein results in increased activity of PLCB2 protein results in increased activity of MAPK3 protein]; daidzein promotes the reaction [GNB1 protein results in increased activity of PLCB2 protein]
daidzein promotes the reaction [ESRRA protein binds to PNRC1 protein]; daidzein promotes the reaction [ESRRB protein binds to PNRC1 protein]; daidzein promotes the reaction [ESRRG protein binds to PNRC1 protein]
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of PRKACA mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of PRPF40A mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of PSPC1 mRNA
[daidzein co-treated with ESR2 protein] results in increased expression of PTGS2 mRNA; daidzein inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA]; daidzein inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] daidzein inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; daidzein inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of PTH1R mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of RASSF5 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of RGS22 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of S1PR3 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of SELPLG mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of SIGLEC10 mRNA
daidzein metabolite inhibits the reaction [SLC10A1 protein results in increased transport of estrone sulfate]; daidzein metabolite promotes the reaction [SLC10A1 protein results in increased transport of estrone sulfate]; estrone sulfate inhibits the reaction [SLC10A1 protein results in increased transport of daidzein metabolite]; Taurocholic Acid inhibits the reaction [SLC10A1 protein results in increased transport of daidzein metabolite]
daidzein inhibits the reaction [SLC10A6 protein results in increased transport of estrone sulfate]; daidzein metabolite inhibits the reaction [SLC10A6 protein results in increased transport of estrone sulfate]; estrone sulfate inhibits the reaction [SLC10A6 protein results in increased transport of daidzein metabolite]
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of SLC16A1 mRNA
SLCO2B1 protein results in increased transport of daidzein metabolite daidzein inhibits the reaction [SLCO2B1 protein results in increased transport of estrone sulfate]; daidzein metabolite inhibits the reaction [SLCO2B1 protein results in increased transport of estrone sulfate]; estrone sulfate inhibits the reaction [SLCO2B1 protein results in increased transport of daidzein metabolite]
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of SNX30 mRNA
daidzein results in increased expression of SOD2 protein SOD2 protein affects the susceptibility to daidzein fulvestrant inhibits the reaction [daidzein results in increased expression of SOD2 protein]
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of SSC5D mRNA
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of STAR mRNA; [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of STAR protein
daidzein inhibits the reaction [Lipopolysaccharides affects the localization of and results in increased activity of STAT1 protein alternative form]; daidzein inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of STAT1 protein]
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of STYXL1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of SUMO1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of TC2N mRNA
[daidzein binds to THRB protein] promotes the reaction [NCOA1 protein binds to THRB protein]; daidzein promotes the reaction [NCOA1 protein binds to THRB protein]; daidzein promotes the reaction [Triiodothyronine results in increased activity of THRB protein]
[Genistein co-treated with daidzein] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF protein]; daidzein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; daidzein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
Fulvestrant inhibits the reaction [daidzein results in increased expression of TNFRSF11B mRNA]; Fulvestrant inhibits the reaction [daidzein results in increased expression of TNFRSF11B protein] daidzein results in increased expression of TNFRSF11B mRNA; daidzein results in increased expression of TNFRSF11B protein
Fulvestrant inhibits the reaction [daidzein results in decreased expression of TNFSF11 mRNA]; Fulvestrant inhibits the reaction [daidzein results in decreased expression of TNFSF11 protein] daidzein results in decreased expression of TNFSF11 mRNA; daidzein results in decreased expression of TNFSF11 protein
daidzein results in decreased expression of TP53I11 mRNA [daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of TP53I11 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of VCPIP1 mRNA
daidzin results in increased expression of ACHE mRNA 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline inhibits the reaction [daidzin results in increased expression of ACHE mRNA]; 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline inhibits the reaction [daidzin results in increased expression of and results in increased activity of ACHE protein]; daidzin results in increased expression of and results in increased activity of ACHE protein
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of ACSL3 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of ALDH1A2 mRNA
daidzin inhibits the reaction [ALDH2 protein results in increased hydrolysis of 4-nitrophenyl acetate]; daidzin inhibits the reaction [ALDH2 protein results in increased oxidation of propionaldehyde]
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of ANPEP mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of ATOH8 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of BCKDK mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of BPGM mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CABP5 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of CACYBP mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CASP8AP2 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CD200R1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of CFAP251 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CYBRD1 mRNA
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of CYP11A1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of DENND2D mRNA
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased expression of DNMT1 mRNA
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased expression of DNMT3A mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of DPP9 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of EDRF1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of EFHD1 mRNA
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased expression of ESR2 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of FAM171A2 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of FAM180A mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of FAM210B mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of FAM241B mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of FGD6 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of FHL2 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of GALNT15 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of GNG5 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of HIPK4 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of HMCN1 mRNA
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of HSD3B1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of IL6R mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of ISG20L2 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of KDM5A mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of KITLG mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of KNSTRN mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of LDLRAP1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of LMOD1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of LRG1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of LSR mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of MRPL33 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of MTMR11 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of MYOF mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of NR4A1 mRNA
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of NR5A1 mRNA; [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of NR5A1 protein; [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased methylation of NR5A1 promoter; decitabine inhibits the reaction [[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of NR5A1 mRNA]
daidzin results in increased expression of PRIMA1 mRNA 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline inhibits the reaction [daidzin results in increased expression of PRIMA1 mRNA]
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of PRKACA mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of PRPF40A mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of PSPC1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of PTH1R mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of RASSF5 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of RGS22 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of S1PR3 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of SELPLG mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of SIGLEC10 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of SLC16A1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of SNX30 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of SSC5D mRNA
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of STAR mRNA; [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of STAR protein
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of STYXL1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of SUMO1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of TC2N mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of TP53I11 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of VCPIP1 mRNA
Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 protein]
Ellagic Acid inhibits the reaction [AGT protein results in decreased abundance of NADP]; Ellagic Acid inhibits the reaction [AGT protein results in increased activity of CASP3 protein]; Ellagic Acid inhibits the reaction [AGT protein results in increased activity of RELA protein]; Ellagic Acid inhibits the reaction [AGT protein results in increased expression of AGTR1 protein]; Ellagic Acid inhibits the reaction [AGT protein results in increased expression of CYBA mRNA]; Ellagic Acid inhibits the reaction [AGT protein results in increased expression of MYH7 mRNA]; Ellagic Acid inhibits the reaction [AGT protein results in increased expression of NCF2 mRNA]; Ellagic Acid inhibits the reaction [AGT protein results in increased expression of NOS2 mRNA]; Ellagic Acid inhibits the reaction [AGT protein results in increased expression of NPPA mRNA]; Ellagic Acid inhibits the reaction [AGT protein results in increased expression of NPPB mRNA]; Ellagic Acid inhibits the reaction [AGT protein results in increased phosphorylation of MAPK1 protein]; Ellagic Acid inhibits the reaction [AGT protein results in increased phosphorylation of MAPK3 protein]
Ellagic Acid results in increased phosphorylation of AKT1 protein Ellagic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of AKT1 protein]
Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of BAX mRNA] Ellagic Acid results in increased expression of BAX mRNA
Ellagic Acid results in increased expression of BCL2 protein Ellagic Acid results in decreased expression of BCL2 mRNA Ellagic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of BCL2 protein]; Ellagic Acid inhibits the reaction [sodium arsenate results in decreased expression of BCL2 mRNA] [Ellagic Acid co-treated with resveratrol] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA]
Ellagic Acid results in increased expression of CASP3 mRNA Ellagic Acid inhibits the reaction [AGT protein results in increased activity of CASP3 protein]; Ellagic Acid inhibits the reaction [Aluminum Chloride results in increased expression of CASP3 protein]; Ellagic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of CASP3 protein]; Ellagic Acid inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein]; Ellagic Acid inhibits the reaction [sodium arsenate results in increased activity of CASP3 protein]; Ellagic Acid inhibits the reaction [Streptozocin results in increased expression of CASP3 protein]; Ellagic Acid promotes the reaction [sinapinic acid inhibits the reaction [Streptozocin results in increased expression of CASP3 protein]]; sinapinic acid promotes the reaction [Ellagic Acid inhibits the reaction [Streptozocin results in increased expression of CASP3 protein]] Ellagic Acid results in increased expression of and results in increased activity of CASP3 protein Ellagic Acid results in increased activity of CASP3 protein Ellagic Acid results in decreased activity of CASP3 protein Ellagic Acid results in decreased expression of CASP3 mRNA
Ellagic Acid results in increased activity of CAT protein Ellagic Acid inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased activity of CAT protein]; Ellagic Acid inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein]; Ellagic Acid inhibits the reaction [chromium hexavalent ion results in decreased activity of CAT protein]; Ellagic Acid inhibits the reaction [sodium arsenite results in decreased activity of CAT protein]
[resveratrol co-treated with Ellagic Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CDKN1A mRNA] [Ellagic Acid co-treated with Quercetin] results in increased expression of CDKN1A mRNA; Ellagic Acid promotes the reaction [Quercetin results in increased expression of CDKN1A protein]; pifithrin inhibits the reaction [Ellagic Acid promotes the reaction [Quercetin results in increased expression of CDKN1A protein]] Ellagic Acid results in increased expression of CDKN1A protein
Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of CTSK mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of CTSK protein]
Ellagic Acid results in decreased activity of CYP1B1 protein [Ellagic Acid co-treated with Plant Extracts] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1B1 mRNA]; [Ellagic Acid co-treated with resveratrol] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1B1 mRNA]
[Ellagic Acid co-treated with Plant Extracts] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of FOS mRNA]; [Ellagic Acid co-treated with Resveratrol] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of FOS mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of FOS protein]
Ellagic Acid inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of GPT protein]; Ellagic Acid inhibits the reaction [sodium arsenite results in increased expression of GPT protein] Ellagic Acid inhibits the reaction [Diquat results in increased activity of GPT protein]
Ellagic Acid inhibits the reaction [sodium arsenite results in decreased expression of GPX1 mRNA] Ellagic Acid inhibits the reaction [Diquat results in decreased expression of GPX1 mRNA]
Ellagic Acid results in increased expression of HMOX1 mRNA; Ellagic Acid results in increased expression of HMOX1 protein Ellagic Acid inhibits the reaction [Diquat results in decreased expression of HMOX1 mRNA] [Paraquat co-treated with Ellagic Acid] results in increased expression of HMOX1 mRNA; [Paraquat co-treated with Ellagic Acid] results in increased expression of HMOX1 protein
[Ellagic Acid co-treated with Plant Extracts] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased mutagenesis of HRAS gene]; [Ellagic Acid co-treated with resveratrol] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased mutagenesis of HRAS gene]
Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of IFNG mRNA]; Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of IFNG protein]
Ellagic Acid results in decreased expression of IL1B mRNA Ellagic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of IL1B protein]; Ellagic Acid inhibits the reaction [Glucose results in increased expression of IL1B protein]; Ellagic Acid inhibits the reaction [Isoproterenol results in increased expression of IL1B mRNA]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of IL1B protein]; Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of IL1B mRNA]; Ellagic Acid inhibits the reaction [sodium arsenite results in increased expression of IL1B protein] Ellagic Acid inhibits the reaction [IL1B protein results in increased secretion of CXCL8 protein]
Ellagic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of IL6 protein]; Ellagic Acid inhibits the reaction [Glucose results in increased expression of IL6 protein]; Ellagic Acid inhibits the reaction [Isoproterenol results in increased expression of IL6 mRNA]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of IL6 protein]
Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased phosphorylation of MAPK1 protein] Ellagic Acid inhibits the reaction [AGT protein results in increased phosphorylation of MAPK1 protein]
Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased phosphorylation of MAPK3 protein] Ellagic Acid inhibits the reaction [AGT protein results in increased phosphorylation of MAPK3 protein]
Ellagic Acid results in decreased activity of and results in decreased secretion of MMP2 protein; zinc chloride inhibits the reaction [Ellagic Acid results in decreased activity of and results in decreased secretion of MMP2 protein] Ellagic Acid results in decreased expression of MMP2 mRNA Ellagic Acid results in decreased activity of MMP2 protein
Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 protein]
Ellagic Acid affects the localization of NFE2L2 protein Ellagic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of NFE2L2 protein] Ellagic Acid results in increased expression of NFE2L2 mRNA [Ellagic Acid co-treated with Diquat] results in increased expression of NFE2L2 mRNA; Ellagic Acid inhibits the reaction [Diquat results in decreased expression of NFE2L2 mRNA]; Ellagic Acid inhibits the reaction [sodium arsenate results in decreased expression of NFE2L2 mRNA] [Paraquat co-treated with Ellagic Acid] results in increased expression of and affects the localization of NFE2L2 protein; [Paraquat co-treated with Ellagic Acid] results in increased expression of NFE2L2 mRNA; Ellagic Acid results in increased expression of and affects the localization of NFE2L2 protein Ellagic Acid results in increased expression of NFE2L2 mRNA; Ellagic Acid results in increased expression of NFE2L2 protein NFE2L2 protein affects the susceptibility to Ellagic Acid
Ellagic Acid inhibits the reaction [AGT protein results in increased expression of NOS2 mRNA]; Ellagic Acid inhibits the reaction [Doxorubicin results in increased expression of NOS2 protein] Ellagic Acid results in decreased expression of NOS2 mRNA
Ellagic Acid results in increased expression of NQO1 mRNA; Ellagic Acid results in increased expression of NQO1 protein Ellagic Acid inhibits the reaction [Diquat results in decreased expression of NQO1 mRNA] [Paraquat co-treated with Ellagic Acid] results in increased expression of NQO1 mRNA; [Paraquat co-treated with Ellagic Acid] results in increased expression of NQO1 protein
Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of PPARGC1A mRNA] Ellagic Acid results in decreased expression of PPARGC1A mRNA
Ellagic Acid inhibits the reaction [phosalone results in increased expression of RB1 mRNA]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of RB1 protein]
Ellagic Acid results in increased expression of RECK mRNA; Ellagic Acid results in increased expression of RECK protein zinc chloride inhibits the reaction [Ellagic Acid results in increased expression of RECK mRNA]; zinc chloride inhibits the reaction [Ellagic Acid results in increased expression of RECK protein]
Ellagic Acid results in decreased expression of RELA mRNA Ellagic Acid inhibits the reaction [TNF protein affects the localization of and results in increased activity of RELA protein] Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased phosphorylation of RELA protein] Ellagic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of RELA protein]; Ellagic Acid inhibits the reaction [AGT protein results in increased activity of RELA protein]; Ellagic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of RELA protein]; Ellagic Acid inhibits the reaction [Glucose results in increased expression of RELA protein]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of RELA protein]
Ellagic Acid inhibits the reaction [Aluminum Chloride results in decreased expression of SOD1 mRNA]; Ellagic Acid inhibits the reaction [Aluminum Chloride results in decreased expression of SOD1 protein]
Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of SRC mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of SRC protein]
Ellagic Acid results in increased expression of STAR mRNA Ellagic Acid inhibits the reaction [sodium arsenate results in decreased expression of STAR mRNA]
Ellagic Acid inhibits the reaction [Estradiol results in increased expression of TERT mRNA alternative form] Ellagic Acid inhibits the reaction [phosalone results in decreased activity of TERT protein] Ellagic Acid results in increased expression of TERT mRNA alternative form
Ellagic Acid results in increased expression of TGFB1 mRNA Ellagic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of TGFB1 protein]
Ellagic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [chromium hexavalent ion results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [Doxorubicin results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [Glucose results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [Isoproterenol results in increased expression of TNF mRNA]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of TNF mRNA]; Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [sodium arsenite results in increased expression of TNF protein] Ellagic Acid inhibits the reaction [TNF protein affects the localization of and results in increased activity of RELA protein]; Ellagic Acid inhibits the reaction [TNF protein results in increased activity of and affects the secretion of CXCL8 protein] Ellagic Acid results in decreased expression of TNF mRNA
Ellagic Acid inhibits the reaction [TNFSF11 protein binds to TNFRSF11A protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of CTSK mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of CTSK protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of FOS protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of SRC mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of SRC protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased phosphorylation of MAPK1 protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased phosphorylation of MAPK3 protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased phosphorylation of RELA protein] Ellagic Acid binds to TNFSF11 protein
Ellagic Acid results in increased expression of TP53 mRNA; Ellagic Acid results in increased expression of TP53 protein Ellagic Acid promotes the reaction [Quercetin results in increased phosphorylation of TP53 protein]; pifithrin inhibits the reaction [Ellagic Acid promotes the reaction [Quercetin results in increased phosphorylation of TP53 protein]] Ellagic Acid inhibits the reaction [phosalone results in increased expression of TP53 mRNA]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of TP53 protein]
Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycochenodeoxycholic Acid]; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycocholic Acid]; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurochenodeoxycholic Acid]; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurocholic Acid]
Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycochenodeoxycholic Acid]; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycocholic Acid]; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurochenodeoxycholic Acid]; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurocholic Acid]
Acetylcysteine inhibits the reaction [formononetin results in increased expression of ABCB1 mRNA]; formononetin inhibits the reaction [Epirubicin results in increased expression of ABCB1 mRNA]; formononetin promotes the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]] formononetin results in decreased activity of ABCB1 protein formononetin affects the activity of ABCB1 protein
formononetin affects the activity of ABCC1 protein formononetin results in decreased expression of ABCC1 mRNA Acetylcysteine inhibits the reaction [formononetin results in decreased expression of ABCC1 mRNA]; formononetin inhibits the reaction [Epirubicin results in increased expression of ABCC1 mRNA]
Acetylcysteine inhibits the reaction [formononetin results in decreased expression of ABCC2 mRNA]; formononetin inhibits the reaction [Epirubicin results in increased expression of ABCC2 mRNA] formononetin promotes the reaction [Cisplatin results in increased expression of ABCC2 mRNA]
formononetin inhibits the reaction [Streptozocin results in increased activity of ACP5 protein]; formononetin inhibits the reaction [Streptozocin results in increased expression of ACP5 mRNA]
formononetin promotes the reaction [Hydrogen Peroxide results in increased phosphorylation of AKT1 protein]; Wortmannin inhibits the reaction [formononetin promotes the reaction [Hydrogen Peroxide results in increased phosphorylation of AKT1 protein]] formononetin decreases phosphorylation of AKT1 protein in lung
formononetin promotes the reaction [Epirubicin results in increased expression of BAX mRNA] formononetin inhibits the reaction [Cisplatin results in increased expression of BAX protein]
formononetin results in decreased expression of BCL2 mRNA formononetin inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein] formononetin promotes the reaction [Cisplatin results in increased expression of BCL2 protein]
Acetylcysteine inhibits the reaction [formononetin results in increased expression of CASP3 mRNA]; Epirubicin promotes the reaction [formononetin results in increased activity of CASP3 protein]; Epirubicin promotes the reaction [formononetin results in increased expression of CASP3 mRNA]; formononetin inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]; formononetin promotes the reaction [Epirubicin results in increased activity of CASP3 protein]; formononetin promotes the reaction [Epirubicin results in increased expression of CASP3 mRNA] formononetin increases activity of CASP3 protein in lung formononetin inhibits the reaction [Cisplatin results in increased expression of CASP3 protein modified form]
Acetylcysteine inhibits the reaction [formononetin results in increased expression of CASP8 mRNA]; Epirubicin promotes the reaction [formononetin results in increased activity of CASP8 protein]; Epirubicin promotes the reaction [formononetin results in increased expression of CASP8 mRNA]
Acetylcysteine inhibits the reaction [formononetin results in increased expression of CASP9 mRNA]; Epirubicin promotes the reaction [formononetin results in increased activity of CASP9 protein]; Epirubicin promotes the reaction [formononetin results in increased expression of CASP9 mRNA]; formononetin promotes the reaction [Epirubicin results in increased activity of CASP9 protein]; formononetin promotes the reaction [Epirubicin results in increased expression of CASP9 mRNA]
formononetin results in increased expression of CCNB1 protein XI-006 inhibits the reaction [formononetin results in increased expression of CCNB1 protein]
formononetin results in increased expression of CCND1 protein XI-006 inhibits the reaction [formononetin results in increased expression of CCND1 protein]
formononetin inhibits the reaction [Streptozocin results in increased expression of CTSK mRNA]; formononetin inhibits the reaction [Streptozocin results in increased expression of CTSK protein]
CYP1A1 protein results in increased hydroxylation of formononetin formononetin results in increased expression of CYP1A1 mRNA fulvestrant promotes the reaction [formononetin results in increased expression of CYP1A1 mRNA] CYP1A1 protein results in decreased methylation of formononetin
formononetin binds to ESR1 protein [Lipopolysaccharides co-treated with formononetin] results in increased expression of ESR1 protein formononetin binds to and results in increased activity of ESR1 protein
formononetin inhibits the reaction [Streptozocin results in increased expression of FOS mRNA]; formononetin inhibits the reaction [Streptozocin results in increased expression of FOS protein]
[formononetin co-treated with Hydrogen Peroxide] results in increased expression of GCLM protein; formononetin promotes the reaction [Hydrogen Peroxide results in increased expression of GCLM mRNA]; NFE2L2 protein affects the reaction [formononetin promotes the reaction [Hydrogen Peroxide results in increased expression of GCLM mRNA]]; Wortmannin inhibits the reaction [formononetin promotes the reaction [Hydrogen Peroxide results in increased expression of GCLM mRNA]]
formononetin results in increased expression of HIF1A mRNA; formononetin results in increased expression of HIF1A protein formononetin results in decreased degradation of and results in increased expression of HIF1A protein modified form; formononetin results in increased expression of and results in decreased degradation of HIF1A protein
[formononetin co-treated with Hydrogen Peroxide] results in increased expression of HMOX1 protein; formononetin promotes the reaction [Hydrogen Peroxide results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [formononetin promotes the reaction [Hydrogen Peroxide results in increased expression of HMOX1 mRNA]]; Wortmannin inhibits the reaction [formononetin promotes the reaction [Hydrogen Peroxide results in increased expression of HMOX1 mRNA]] formononetin inhibits the reaction [Glucose results in decreased expression of HMOX1 mRNA]
formononetin inhibits the reaction [Streptozocin results in increased expression of JUN mRNA]; formononetin inhibits the reaction [Streptozocin results in increased expression of JUN protein]
formononetin inhibits the reaction [Streptozocin results in increased expression of MMP9 mRNA]; formononetin inhibits the reaction [Streptozocin results in increased expression of MMP9 protein]
formononetin inhibits the reaction [Streptozocin results in increased expression of NFATC1 mRNA]; formononetin inhibits the reaction [Streptozocin results in increased expression of NFATC1 protein]
[formononetin co-treated with Hydrogen Peroxide] results in increased expression of NFE2L2 mRNA; formononetin promotes the reaction [Hydrogen Peroxide affects the localization of NFE2L2 protein]; NFE2L2 protein affects the reaction [[formononetin co-treated with Hydrogen Peroxide] results in increased expression of NQO1 mRNA]; NFE2L2 protein affects the reaction [[formononetin co-treated with Hydrogen Peroxide] results in increased expression of TXNRD1 mRNA]; NFE2L2 protein affects the reaction [formononetin promotes the reaction [Hydrogen Peroxide results in increased expression of GCLM mRNA]]; NFE2L2 protein affects the reaction [formononetin promotes the reaction [Hydrogen Peroxide results in increased expression of HMOX1 mRNA]]; Wortmannin inhibits the reaction [formononetin promotes the reaction [Hydrogen Peroxide affects the localization of NFE2L2 protein]] formononetin inhibits the reaction [Lipopolysaccharides results in decreased expression of NFE2L2 mRNA]; formononetin inhibits the reaction [Lipopolysaccharides results in decreased expression of NFE2L2 protein]
formononetin inhibits the reaction [Glucose results in decreased expression of NGF mRNA]; formononetin inhibits the reaction [Glucose results in decreased secretion of and results in decreased expression of NGF protein]
formononetin results in increased expression of NOS3 mRNA formononetin results in increased phosphorylation of and results in increased activity of NOS3 protein
[formononetin co-treated with Hydrogen Peroxide] results in increased expression of NQO1 mRNA; [formononetin co-treated with Hydrogen Peroxide] results in increased expression of NQO1 protein; NFE2L2 protein affects the reaction [[formononetin co-treated with Hydrogen Peroxide] results in increased expression of NQO1 mRNA]; Wortmannin inhibits the reaction [[formononetin co-treated with Hydrogen Peroxide] results in increased expression of NQO1 mRNA]
formononetin inhibits the reaction [Glucose results in decreased expression of PPARGC1A mRNA]; formononetin inhibits the reaction [Glucose results in decreased expression of PPARGC1A protein]
formononetin results in increased phosphorylation of PRKAA1 protein Lipopolysaccharides promotes the reaction [formononetin results in increased phosphorylation of PRKAA1 protein]
formononetin inhibits the reaction [Glucose results in decreased expression of SIRT1 mRNA]; formononetin inhibits the reaction [Glucose results in decreased expression of SIRT1 protein]
formononetin binds to SIRT3 protein formononetin inhibits the reaction [Glucose results in decreased expression of SIRT3 mRNA]; formononetin inhibits the reaction [Glucose results in decreased expression of SIRT3 protein]
formononetin inhibits the reaction [Glucose results in decreased expression of SOD1 mRNA]; formononetin inhibits the reaction [Glucose results in decreased expression of SOD1 protein]
formononetin inhibits the reaction [Glucose results in decreased expression of SOD2 mRNA]; formononetin inhibits the reaction [Glucose results in decreased expression of SOD2 protein]
formononetin inhibits the reaction [Cisplatin results in increased expression of TP53 protein] formononetin results in decreased expression of TP53 protein XI-006 inhibits the reaction [formononetin results in decreased expression of TP53 protein]
[formononetin co-treated with Hydrogen Peroxide] results in increased expression of TXNRD1 mRNA; [formononetin co-treated with Hydrogen Peroxide] results in increased expression of TXNRD1 protein; NFE2L2 protein affects the reaction [[formononetin co-treated with Hydrogen Peroxide] results in increased expression of TXNRD1 mRNA]; Wortmannin inhibits the reaction [[formononetin co-treated with Hydrogen Peroxide] results in increased expression of TXNRD1 mRNA]
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of AEBP1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of AEBP1 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of AEBP1 mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ALOX5AP mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of ALOX5AP mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of ALOX5AP mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ARPP21 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of ARPP21 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of ARPP21 mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ASIC2 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of ASIC2 mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of C1R mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of C1R mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of C3AR1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of C3AR1 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of C3AR1 mRNA
[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased activity of CASP3 protein; Zinc inhibits the reaction [[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased activity of CASP3 protein]
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of CD36 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of CD36 mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of CIDEC mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of CIDEC mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of CLCN3 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of CLCN3 mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of CLCN3 mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of DCN mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of DCN mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of DUSP3 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of DUSP3 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of DUSP3 mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of ELOVL3 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of ELOVL3 mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of ELOVL3 mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of ESR2 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of ESR2 mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ETV6 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of ETV6 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of ETV6 mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of FADS2 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of FADS2 mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of FAIM mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of FAIM mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of FAIM mRNA
[Stavudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of FASN mRNA; [Stavudine co-treated with Lamivudine] results in increased expression of FASN mRNA; [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of FASN mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of FASN mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of G0S2 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of G0S2 mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of GANC mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of GANC mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of GANC mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of GUCY1B1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of GUCY1B1 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of GUCY1B1 mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of HADH mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of HADH mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of HADH mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of HCN1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of HCN1 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of HCN1 mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of H4C9 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of H4C9 mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of IKZF4 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of IKZF4 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of IKZF4 mRNA
[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased expression of IL1B protein; Zinc inhibits the reaction [[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased expression of IL1B protein]
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of KLHL28 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of KLHL28 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of KLHL28 mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of LAMC2 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of LAMC2 mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of LEP mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of LEP mRNA
Lamivudine results in decreased expression of LPL mRNA [Stavudine co-treated with Lamivudine co-treated with Indinavir] affects the expression of LPL mRNA; [Stavudine co-treated with Lamivudine co-treated with Nelfinavir] results in decreased expression of LPL mRNA; [Stavudine co-treated with Lamivudine] affects the expression of LPL mRNA; [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of LPL mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of LPL mRNA
[Stavudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ME1 mRNA; [Stavudine co-treated with Lamivudine co-treated with Nelfinavir] results in decreased expression of ME1 mRNA; [Stavudine co-treated with Lamivudine] results in increased expression of ME1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ME1 mRNA; [Zidovudine co-treated with Lamivudine] affects the expression of ME1 mRNA Lamivudine results in increased expression of ME1 mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of MGAT4C mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of MGAT4C mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of MGAT4C mRNA
[efavirenz co-treated with Lamivudine co-treated with Tenofovir] promotes the reaction [[isoniazid, pyrazinamide, rifampin drug combination co-treated with Ethambutol] results in increased activity of MPO protein]; [efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased activity of MPO protein
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of MRAP mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of MRAP mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of MYOD1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of MYOD1 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of MYOD1 mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of NAP1L5 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of NAP1L5 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of NAP1L5 mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of NOCT mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of NOCT mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of NOCT mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of NUP210 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of NUP210 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of NUP210 mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of OAZ3 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of OAZ3 mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of PCDH15 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of PCDH15 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of PCDH15 mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of PFKFB3 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of PFKFB3 mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of PHF6 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of PHF6 mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of PHF6 mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of PIDD1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of PIDD1 mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of PIWIL2 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of PIWIL2 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of PIWIL2 mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of PPN mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of PPN mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of POU5F1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of POU5F1 mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of POU5F1 mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of PRDM1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of PRDM1 mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of REEP6 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of REEP6 mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of REEP6 mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of RNF151 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of RNF151 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of RNF151 mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of RPAIN mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of RPAIN mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of RPAIN mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of S100A8 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of S100A8 mRNA
SLC25A19 protein affects the susceptibility to [Stavudine co-treated with Lamivudine co-treated with Indinavir]; SLC25A19 protein affects the susceptibility to [Zidovudine co-treated with Lamivudine co-treated with Indinavir] [Zidovudine co-treated with Lamivudine] results in decreased expression of SLC25A19 mRNA
[Lamivudine co-treated with IFNA2 protein] results in increased expression of SLC6A4 mRNA; Lamivudine promotes the reaction [SLC6A4 protein results in increased uptake of Serotonin]; Lamivudine results in increased expression of and results in increased activity of SLC6A4 protein Lamivudine results in increased expression of SLC6A4 mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of SPINK5 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of SPINK5 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of SPINK5 mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of TIMP2 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of TIMP2 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of TIMP2 mRNA
[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased expression of TNF protein; Zinc inhibits the reaction [[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased expression of TNF protein]
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of TRIM42 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of TRIM42 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of TRIM42 mRNA
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of WNT10A mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of WNT10A mRNA
Plicamycin inhibits the reaction [cobaltous chloride results in increased expression of ATP7A mRNA] Plicamycin results in decreased expression of ATP7A mRNA
Plicamycin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BNIP3L mRNA] Plicamycin results in decreased expression of BNIP3L mRNA
Plicamycin inhibits the reaction [[Cyclosporine co-treated with NGF protein] results in increased expression of CDKN1A mRNA]; Plicamycin inhibits the reaction [SP1 protein binds to CDKN1A promoter]
Plicamycin inhibits the reaction [cobaltous chloride results in increased expression of CYBRD1 mRNA] Plicamycin results in decreased expression of CYBRD1 mRNA
[Plicamycin results in decreased activity of SP1 protein] inhibits the reaction [cobaltous chloride results in increased expression of DDIT4 mRNA]; [Plicamycin results in decreased activity of SP1 protein] inhibits the reaction [cobaltous chloride results in increased expression of DDIT4 protein]
Plicamycin inhibits the reaction [cobaltous chloride results in increased expression of SLC11A2 mRNA] Plicamycin results in decreased expression of SLC11A2 mRNA
Plicamycin results in decreased expression of SLC40A1 mRNA Plicamycin inhibits the reaction [cobaltous chloride results in increased expression of SLC40A1 mRNA]
Plicamycin results in decreased activity of SP1 protein Plicamycin results in decreased expression of SP1 protein Plicamycin results in decreased expression of SP1 mRNA [Plicamycin inhibits the reaction [SP1 protein binds to TNFSF10 promoter]] which results in increased expression of TNFSF10 protein; [Plicamycin results in decreased activity of SP1 protein] inhibits the reaction [cobaltous chloride results in increased expression of DDIT4 mRNA]; [Plicamycin results in decreased activity of SP1 protein] inhibits the reaction [cobaltous chloride results in increased expression of DDIT4 protein]; Plicamycin inhibits the reaction [SP1 protein binds to CDKN1A promoter]; Plicamycin inhibits the reaction [SP1 protein binds to TNFSF10 promoter]
[Plicamycin inhibits the reaction [SP1 protein binds to TNFSF10 promoter]] which results in increased expression of TNFSF10 protein; Plicamycin inhibits the reaction [SP1 protein binds to TNFSF10 promoter]
neobavaisoflavone inhibits the reaction [[CYP2E1 protein results in increased metabolism of 4-nitrophenol] which results in increased chemical synthesis of 4-nitrocatechol] neobavaisoflavone results in decreased activity of CYP2E1 protein
pamidronate results in increased cleavage of and results in increased activity of CASP3 protein pamidronate results in increased cleavage of CASP3 protein
[Arsenic Trioxide co-treated with Pamidronate] promotes the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Pamidronate promotes the reaction [EGF protein results in increased phosphorylation of EGFR protein]
[Arsenic Trioxide co-treated with Pamidronate] promotes the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Pamidronate promotes the reaction [EGF protein results in increased phosphorylation of EGFR protein]
Pamidronate results in increased secretion of IL1B protein [Pamidronate co-treated with Acetylmuramyl-Alanyl-Isoglutamine] results in increased secretion of IL1B protein; [Pamidronate co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein; geraniol inhibits the reaction [[Pamidronate co-treated with Acetylmuramyl-Alanyl-Isoglutamine] results in increased secretion of IL1B protein]; geraniol inhibits the reaction [[Pamidronate co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]; Pamidronate promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL1B protein]
pamidronate results in increased cleavage of PARP1 protein [pamidronate co-treated with ultra-high molecular weight polyethylene] results in increased cleavage of PARP1 protein
pamidronate results in decreased activity of PON1 protein [pamidronate results in decreased activity of PON1 protein] which results in decreased metabolism of homocysteine thiolactone; [pamidronate results in decreased activity of PON1 protein] which results in decreased metabolism of Paraoxon; [pamidronate results in decreased activity of PON1 protein] which results in decreased metabolism of phenyl acetate
Acetylcysteine inhibits the reaction [Arsenic Trioxide promotes the reaction [Pamidronate results in decreased expression of and results in decreased activity of PTPN1 protein]]; Acetylcysteine inhibits the reaction [Pamidronate promotes the reaction [Arsenic Trioxide results in decreased expression of and results in decreased activity of PTPN1 protein]]; Acetylcysteine inhibits the reaction [Pamidronate results in decreased expression of and results in decreased activity of PTPN1 protein]; Arsenic Trioxide promotes the reaction [Pamidronate results in decreased expression of and results in decreased activity of PTPN1 protein]; Pamidronate promotes the reaction [Arsenic Trioxide results in decreased expression of and results in decreased activity of PTPN1 protein]; Pamidronate results in decreased expression of and results in decreased activity of PTPN1 protein
pamidronate increases expression of RAC1 mRNA in cholangiocarcinoma cells, pamidronate decreases expression of RAC1 protein in cholangiocarcinoma cells
pamidronate results in increased expression of TNF protein pamidronate inhibits the reaction [ultra-high molecular weight polyethylene results in increased secretion of TNF protein]
pamidronate inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B mRNA]; pamidronate inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B protein] pamidronate results in increased expression of TNFRSF11B mRNA; pamidronate results in increased expression of TNFRSF11B protein
Chlorpyrifos binds to [DDC protein binds to Pyridoxal Phosphate]; DDC protein binds to Pyridoxal Phosphate; Diazinon binds to [DDC protein binds to Pyridoxal Phosphate]; Glyphosate binds to [DDC protein binds to Pyridoxal Phosphate]; Isoflurophate binds to [DDC protein binds to Pyridoxal Phosphate]; Malathion binds to [DDC protein binds to Pyridoxal Phosphate]; mipafox binds to [DDC protein binds to Pyridoxal Phosphate]; novichok binds to [DDC protein binds to Pyridoxal Phosphate]; O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate binds to [DDC protein binds to Pyridoxal Phosphate]; Paraoxon binds to [DDC protein binds to Pyridoxal Phosphate]; phenyl di-n-pentylphosphinate binds to [DDC protein binds to Pyridoxal Phosphate]; phenylsaligenin cyclic phosphate binds to [DDC protein binds to Pyridoxal Phosphate]; S-(N,N-diethylaminoethyl) isobutyl methylphosphothiolate binds to [DDC protein binds to Pyridoxal Phosphate]; Sarin binds to [DDC protein binds to Pyridoxal Phosphate]; Soman binds to [DDC protein binds to Pyridoxal Phosphate]; tabun binds to [DDC protein binds to Pyridoxal Phosphate]; VX binds to [DDC protein binds to Pyridoxal Phosphate] [DDC protein binds to Pyridoxal Phosphate] which binds to and results in increased metabolism of Levodopa
Chlorpyrifos binds to [GAD1 protein binds to Pyridoxal Phosphate]; Diazinon binds to [GAD1 protein binds to Pyridoxal Phosphate]; GAD1 protein binds to Pyridoxal Phosphate; Glyphosate binds to [GAD1 protein binds to Pyridoxal Phosphate]; Isoflurophate binds to [GAD1 protein binds to Pyridoxal Phosphate]; Malathion binds to [GAD1 protein binds to Pyridoxal Phosphate]; mipafox binds to [GAD1 protein binds to Pyridoxal Phosphate]; novichok binds to [GAD1 protein binds to Pyridoxal Phosphate]; O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate binds to [GAD1 protein binds to Pyridoxal Phosphate]; Paraoxon binds to [GAD1 protein binds to Pyridoxal Phosphate]; phenyl di-n-pentylphosphinate binds to [GAD1 protein binds to Pyridoxal Phosphate]; phenylsaligenin cyclic phosphate binds to [GAD1 protein binds to Pyridoxal Phosphate]; Pyridoxal Phosphate binds to GAD1 protein modified form; S-(N,N-diethylaminoethyl) isobutyl methylphosphothiolate binds to [GAD1 protein binds to Pyridoxal Phosphate]; Sarin binds to [GAD1 protein binds to Pyridoxal Phosphate]; Soman binds to [GAD1 protein binds to Pyridoxal Phosphate]; tabun binds to [GAD1 protein binds to Pyridoxal Phosphate]; VX binds to [GAD1 protein binds to Pyridoxal Phosphate] [GAD1 protein binds to Pyridoxal Phosphate] which binds to and results in increased metabolism of Glutamic Acid Pyridoxal Phosphate results in decreased activity of GAD1 protein Pyridoxal Phosphate results in increased activity of GAD1 protein
Chlorpyrifos binds to [GAD2 protein binds to Pyridoxal Phosphate]; Diazinon binds to [GAD2 protein binds to Pyridoxal Phosphate]; GAD2 protein binds to Pyridoxal Phosphate; Glyphosate binds to [GAD2 protein binds to Pyridoxal Phosphate]; Isoflurophate binds to [GAD2 protein binds to Pyridoxal Phosphate]; Malathion binds to [GAD2 protein binds to Pyridoxal Phosphate]; mipafox binds to [GAD2 protein binds to Pyridoxal Phosphate]; novichok binds to [GAD2 protein binds to Pyridoxal Phosphate]; O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate binds to [GAD2 protein binds to Pyridoxal Phosphate]; Paraoxon binds to [GAD2 protein binds to Pyridoxal Phosphate]; phenyl di-n-pentylphosphinate binds to [GAD2 protein binds to Pyridoxal Phosphate]; phenylsaligenin cyclic phosphate binds to [GAD2 protein binds to Pyridoxal Phosphate]; Pyridoxal Phosphate binds to GAD2 protein; Pyridoxal Phosphate binds to GAD2 protein modified form; S-(N,N-diethylaminoethyl) isobutyl methylphosphothiolate binds to [GAD2 protein binds to Pyridoxal Phosphate]; Sarin binds to [GAD2 protein binds to Pyridoxal Phosphate]; Soman binds to [GAD2 protein binds to Pyridoxal Phosphate]; tabun binds to [GAD2 protein binds to Pyridoxal Phosphate]; VX binds to [GAD2 protein binds to Pyridoxal Phosphate] [GAD2 protein binds to Pyridoxal Phosphate] which binds to and results in increased metabolism of Glutamic Acid
[HDC protein binds to Pyridoxal Phosphate] which binds to and results in increased metabolism of Histidine Chlorpyrifos binds to [HDC protein binds to Pyridoxal Phosphate]; Diazinon binds to [HDC protein binds to Pyridoxal Phosphate]; Glyphosate binds to [HDC protein binds to Pyridoxal Phosphate]; HDC protein binds to Pyridoxal Phosphate; Isoflurophate binds to [HDC protein binds to Pyridoxal Phosphate]; Malathion binds to [HDC protein binds to Pyridoxal Phosphate]; mipafox binds to [HDC protein binds to Pyridoxal Phosphate]; novichok binds to [HDC protein binds to Pyridoxal Phosphate]; O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate binds to [HDC protein binds to Pyridoxal Phosphate]; Paraoxon binds to [HDC protein binds to Pyridoxal Phosphate]; phenyl di-n-pentylphosphinate binds to [HDC protein binds to Pyridoxal Phosphate]; phenylsaligenin cyclic phosphate binds to [HDC protein binds to Pyridoxal Phosphate]; S-(N,N-diethylaminoethyl) isobutyl methylphosphothiolate binds to [HDC protein binds to Pyridoxal Phosphate]; Sarin binds to [HDC protein binds to Pyridoxal Phosphate]; Soman binds to [HDC protein binds to Pyridoxal Phosphate]; tabun binds to [HDC protein binds to Pyridoxal Phosphate]; VX binds to [HDC protein binds to Pyridoxal Phosphate]
Ribavirin inhibits the reaction [CARM1 protein binds to EIF4E promoter]; Ribavirin inhibits the reaction [CARM1 protein binds to VEGFA promoter] Ribavirin results in decreased expression of CARM1 protein
Ribavirin inhibits the reaction [CARM1 protein binds to EIF4E promoter]; Ribavirin inhibits the reaction [Doxorubicin results in increased phosphorylation of EIF4E protein] Ribavirin results in decreased expression of EIF4E mRNA; Ribavirin results in decreased expression of EIF4E protein Ribavirin results in decreased phosphorylation of EIF4E protein
[peginterferon alfa-2b co-treated with Ribavirin] affects the expression of EPO protein; [Ribavirin co-treated with Interferons] results in increased expression of EPO protein Ribavirin results in increased expression of EPO
Ribavirin promotes the reaction [FAS protein results in increased activity of CASP3 protein]; Ribavirin promotes the reaction [FAS protein results in increased activity of CASP7 protein]; Ribavirin promotes the reaction [FAS protein results in increased activity of CASP8 protein]
[Ribavirin co-treated with IFNA2 protein] affects the reaction [Lipopolysaccharides results in increased secretion of IFNG protein]; [Ribavirin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; Ribavirin inhibits the reaction [Lipopolysaccharides results in increased secretion of IFNG protein]; Ribavirin results in increased expression of and results in increased secretion of IFNG protein Ribavirin results in increased expression of IFNG protein Ribavirin results in increased expression of IFNG mRNA; Ribavirin results in increased expression of IFNG protein Ribavirin results in decreased expression of IFNG mRNA
IFNL3 gene polymorphism affects the susceptibility to [Ribavirin co-treated with IFNA2 protein modified form]; IFNL3 gene SNP affects the susceptibility to [peginterferon alfa-2a co-treated with Ribavirin]; IFNL3 protein results in increased susceptibility to [Ribavirin co-treated with IFNA2 protein modified form]
[Ribavirin co-treated with IFNA2 protein] affects the reaction [Lipopolysaccharides results in increased secretion of IL10 protein]; Ribavirin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein]; Ribavirin results in decreased expression of and results in decreased secretion of IL10 protein [peginterferon alfa-2a co-treated with Ribavirin co-treated with Danazol] results in decreased expression of IL10 mRNA; [peginterferon alfa-2a co-treated with Ribavirin] results in increased expression of IL10 mRNA Ribavirin results in decreased expression of IL10 protein Ribavirin results in decreased expression of IL10 mRNA
[Ribavirin co-treated with IFNA2 protein] promotes the reaction [Lipopolysaccharides results in increased secretion of [IL12A protein binds to IL12B protein]]; Ribavirin promotes the reaction [Lipopolysaccharides results in increased secretion of [IL12A protein binds to IL12B protein]]
[Ribavirin co-treated with IFNA2 protein] promotes the reaction [Lipopolysaccharides results in increased secretion of [IL12A protein binds to IL12B protein]]; Ribavirin promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL12B protein]; Ribavirin promotes the reaction [Lipopolysaccharides results in increased secretion of [IL12A protein binds to IL12B protein]]
Ribavirin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein] Ribavirin results in increased expression of IL1B mRNA
[Ribavirin co-treated with IFNA2 protein] promotes the reaction [Lipopolysaccharides results in increased secretion of IL2 protein]; [Ribavirin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; Ribavirin promotes the reaction [Lipopolysaccharides results in increased secretion of IL2 protein]; Ribavirin results in increased expression of and results in increased secretion of IL2 protein Ribavirin results in increased expression of IL2 mRNA; Ribavirin results in increased expression of IL2 protein
Ribavirin results in decreased expression of IL4 mRNA; Ribavirin results in decreased expression of IL4 protein Ribavirin promotes the reaction [Lipopolysaccharides results in increased secretion of IL4 protein]; Ribavirin results in decreased expression of and results in decreased secretion of IL4 protein
Ribavirin results in decreased expression of IL5 mRNA; Ribavirin results in decreased expression of IL5 protein Ribavirin results in decreased expression of and results in decreased secretion of IL5 protein
Ribavirin promotes the reaction [SLC6A4 protein results in increased uptake of Serotonin]; Ribavirin results in increased expression of and results in increased activity of SLC6A4 protein Ribavirin results in increased expression of SLC6A4 mRNA
Ribavirin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Ribavirin results in increased expression of and results in increased secretion of TNF protein [peginterferon alfa-2a co-treated with Ribavirin co-treated with Danazol] results in decreased expression of TNF mRNA Ribavirin results in increased expression of TNF mRNA; Ribavirin results in increased expression of TNF protein
Ribavirin results in increased expression of TP53 protein Ribavirin affects the activity of TP53 protein Ribavirin results in increased expression of TRP53 protein
Ribavirin results in decreased expression of VEGFA mRNA; Ribavirin results in decreased expression of VEGFA protein Ribavirin results in decreased secretion of VEGFA protein Ribavirin inhibits the reaction [CARM1 protein binds to VEGFA promoter]
AADAC mRNA affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; bis(4-nitrophenyl)phosphate inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Isoflurophate inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Phenylmethylsulfonyl Fluoride inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Physostigmine inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Sodium Fluoride inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin] AADAC protein results in increased hydrolysis of Rifampin
Rifampin results in decreased expression of ABCA1 mRNA; Rifampin results in decreased expression of ABCA1 protein Rifampin results in increased expression of ABCA1 mRNA; Rifampin results in increased expression of ABCA1 protein
Rifampin results in decreased expression of ABCB11 mRNA [Rifampin co-treated with Isoniazid] results in decreased expression of ABCB11 protein Rifampin results in decreased expression of ABCB11 protein tanshinone inhibits the reaction [Rifampin results in decreased expression of ABCB11 mRNA]; tanshinone inhibits the reaction [Rifampin results in decreased expression of ABCB11 protein] Rifampin results in decreased activity of ABCB11 protein [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCB11 protein; Rifampin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Rifampin results in decreased expression of ABCB11 mRNA; Rifampin results in decreased expression of ABCB11 protein
[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein; [Rifampin binds to and results in increased activity of NR1I2 protein] promotes the reaction [ABCB1 protein results in decreased uptake of Doxorubicin]; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 protein; Camptothecin inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of ABCB1 protein]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]; pimecrolimus inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA]; Resveratrol inhibits the reaction [Rifampin results in increased expression of ABCB1 protein]; Rifampin promotes the reaction [ABCB1 protein results in increased transport of Digoxin]; Rifampin promotes the reaction [NR1I2 protein binds to ABCB1 promoter] Rifampin results in increased expression of ABCB1 mRNA; Rifampin results in increased expression of ABCB1 protein [Rifampin metabolite results in decreased activity of ABCB1A protein] which results in decreased abundance of Adenosine Triphosphate Rifampin affects the activity of ABCB1 protein
ABCC2 protein affects the export of Rifampin [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCC2 protein Rifampin results in increased expression of ABCC2; Rifampin results in increased expression of ABCC2 mRNA; Rifampin results in increased expression of ABCC2 protein [Rifampin co-treated with ABCC2 gene mutant form] results in increased expression of ABCC3 protein
[Rifampin co-treated with ABCC2 gene mutant form] results in increased expression of ABCC3 protein; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCC3 mRNA; Rifampin inhibits the reaction [Decitabine results in increased expression of ABCC3 mRNA] Rifampin results in increased expression of ABCC3 mRNA Rifampin results in increased activity of ABCC3 protein
Rifampin results in increased expression of ABCG2 mRNA; Rifampin results in increased expression of ABCG2 protein Rifampin promotes the reaction [Dextran Sulfate results in decreased expression of ABCG2 mRNA]; Rifampin promotes the reaction [Lipopolysaccharides results in decreased expression of ABCG2 mRNA]
[Rifampin co-treated with Benzo(a)pyrene] results in increased expression of AHR mRNA; [Rifampin co-treated with Monocrotophos] results in decreased expression of AHR mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of AHR protein; NR1I2 protein inhibits the reaction [[Rifampin co-treated with Benzo(a)pyrene] results in increased expression of AHR mRNA] Rifampin results in increased expression of AHR mRNA; Rifampin results in increased expression of AHR protein
Rifampin results in increased expression of AKR1B10 mRNA pazopanib inhibits the reaction [Rifampin results in increased expression of AKR1B10 mRNA]; pimecrolimus inhibits the reaction [Rifampin results in increased expression of AKR1B10 mRNA]
Rifampin results in decreased expression of APOB mRNA ursodoxicoltaurine inhibits the reaction [Rifampin results in decreased expression of APOB mRNA] Rifampin affects the secretion of APOB protein
ATF4 mutant form inhibits the reaction [Rifampin results in increased expression of HSPA5 protein] Rifampin results in increased expression of ATF4 mRNA; Rifampin results in increased expression of ATF4 protein 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of ATF4 mRNA]; 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of ATF4 protein]
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM protein Rifampin results in decreased expression of ATM mRNA
Rifampin results in increased expression of ATP6V0A1 protein [Rotenone co-treated with Rifampin] results in increased expression of ATP6V0A1 protein; Rifampin inhibits the reaction [Rotenone results in decreased expression of ATP6V0A1 mRNA]; Rotenone inhibits the reaction [Rifampin results in increased expression of ATP6V0A1 protein]
[Isoniazid co-treated with Rifampin] results in increased expression of BAX protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BAX mRNA; [Rifampin co-treated with Cobicistat] results in increased expression of BAX mRNA; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased expression of BAX protein] [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in increased expression of BAX protein Rifampin results in decreased expression of BAX protein
Rifampin results in increased expression of BCL2 protein [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of BCL2 protein [Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein]
Rifampin results in increased expression of BCL2L1 protein [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BCL2L1 mRNA
Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]]; Rifampin inhibits the reaction [[Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of CASP3 protein]; Rifampin inhibits the reaction [Doxorubicin results in increased cleavage of CASP3 protein]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]; Rifampin inhibits the reaction [Staurosporine results in increased cleavage of CASP3 protein]; Rifampin promotes the reaction [Galactosamine results in increased activity of CASP3 protein] [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CASP3 [Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein; HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]
Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A protein
[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of CEBPA mRNA; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA protein]
[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of CEBPB mRNA; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB protein]
[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of CEBPD mRNA; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPD mRNA]
Rifampin results in increased expression of CES2 mRNA; Rifampin results in increased expression of CES2 protein Dichlororibofuranosylbenzimidazole inhibits the reaction [Rifampin results in increased expression of CES2 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CES2 mRNA]
Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form]]; Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form] Rifampin results in increased expression of CFLAR protein
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CXCL10 mRNA Rifampin affects the expression of CXCL10 protein
Rifampin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] Rifampin results in increased activity of CYP1A1 protein Rifampin results in increased expression of CYP1A1 mRNA; Rifampin results in increased expression of CYP1A1 protein [Methylcholanthrene co-treated with Rifampin co-treated with Phenobarbital] results in increased expression of CYP1A1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased activity of CYP1A1 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP1A1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP1A1 protein; [Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP1A1 mRNA; Rifampin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]
[Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP1A2 mRNA; Rifampin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein] Rifampin results in increased expression of CYP1A2 mRNA [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP1A2 protein; [Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 mRNA; [Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 protein; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 mRNA]; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 protein] Rifampin results in increased expression of CYP1A2 mRNA; Rifampin results in increased expression of CYP1A2 protein
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP1B1 mRNA [Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP1B1 mRNA
NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP24A1 mRNA]; Rifampin promotes the reaction [NR1I2 protein binds to CYP24A1 promoter] Rifampin results in increased activity of CYP24A1 protein
Rifampin promotes the reaction [[NR1I2 protein binds to NCOA1 protein] which binds to CYP27A1 gene] Rifampin results in increased expression of CYP27A1 mRNA
Rifampin results in increased expression of CYP2A1 mRNA Rifampin results in increased expression of CYP2A13 mRNA Rifampin results in decreased expression of CYP2A13 mRNA
Rifampin results in increased activity of CYP2B6 protein [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2B10 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP2B10 mRNA Rifampin results in increased expression of CYP2B10 mRNA Rifampin results in increased expression of CYP2B6 mRNA; Rifampin results in increased expression of CYP2B6 protein [Rifampin co-treated with Monocrotophos] results in increased activity of CYP2B6 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2B6 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2B6 protein; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP2B6 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP2B6 mRNA; Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]]]; Dexamethasone promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; GW 3965 inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of and results in increased activity of CYP2B6 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; Rifampin results in increased expression of and results in increased activity of CYP2B6 protein
Rifampin results in increased activity of CYP2C19 protein Rifampin results in increased expression of CYP2C29 mRNA [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2C protein Rifampin results in increased expression of CYP2C19 mRNA; Rifampin results in increased expression of CYP2C19 protein Rifampin results in increased expression of and results in increased activity of CYP2C19 protein
[Rifampin binds to NR1I2 protein] which binds to CYP2C8 promoter [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of BCL2 protein; [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of MCL1 protein; [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in increased expression of BAX protein; Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP2C8 mRNA]; pimecrolimus inhibits the reaction [Rifampin results in increased expression of CYP2C8 mRNA]; Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine] Rifampin results in increased expression of CYP2C8 mRNA; Rifampin results in increased expression of CYP2C8 protein Rifampin results in increased activity of CYP2C8 protein
Rifampin results in increased expression of CYP2D6 mRNA Rifampin results in increased activity of CYP2D6 protein Rifampin results in decreased expression of CYP2D22 mRNA
Rifampin results in increased activity of CYP2E1 protein Rifampin results in decreased expression of CYP2E1 mRNA [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP2E1 protein; [Isoniazid co-treated with Rifampin co-treated with dendrobine] results in decreased expression of CYP2E1 mRNA; [Isoniazid co-treated with Rifampin] results in decreased expression of CYP2E1 mRNA Rifampin results in increased expression of CYP2E1 mRNA; Rifampin results in increased expression of CYP2E1 protein [Rifampin co-treated with Monocrotophos] results in increased activity of CYP2E1 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2E1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2E1 protein [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein; [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; Rifampin inhibits the reaction [Isoniazid results in increased expression of CYP2E1 protein]
[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]; arsenite inhibits the reaction [Rifampin results in increased expression of and results in increased activity of CYP3A2 protein]; arsenite inhibits the reaction [Rifampin results in increased expression of CYP3A2 mRNA]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]; Rifampin results in increased expression of and results in increased activity of CYP3A2 protein Rifampin affects the activity of CYP3A4 protein Rifampin results in increased expression of CYP3A4; Rifampin results in increased expression of CYP3A4 mRNA; Rifampin results in increased expression of CYP3A4 mRNA alternative form; Rifampin results in increased expression of CYP3A4 protein [[Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein] which results in increased metabolism of and results in increased activity of and results in increased susceptibility to Cobicistat; [Dimethyl Sulfoxide results in increased susceptibility to Rifampin] which results in increased expression of CYP3A4 mRNA; [HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Methylcholanthrene co-treated with Rifampin co-treated with Phenobarbital] results in increased expression of CYP3A4 mRNA; [NR1I2 protein binds to NCOR2 protein] inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; [NR1I2 protein co-treated with Rifampin] results in decreased expression of CYP3A4 mRNA; [PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [Rifampin binds to CYP3A4 promoter] which results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with Monocrotophos] results in increased activity of CYP3A4 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP3A4 protein; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [Rifampin results in increased expression of CYP3A4 protein] which results in decreased abundance of Ethinyl Estradiol; [Rifampin results in increased expression of CYP3A4 protein] which results in decreased abundance of Midazolam; [Rifampin results in increased expression of CYP3A4 protein] which results in increased hydroxylation of Testosterone; [Rifampin results in increased expression of NR1I2 protein] which results in increased expression of and results in increased activity of CYP3A4 protein; [RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; AADAC mRNA affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [Rifampin results in increased activity of CYP3A4 protein]; allyl isothiocyanate inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; Arsenic Trioxide inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; Calcitriol promotes the reaction [Rifampin results in increased activity of CYP3A4 protein]; Calcitriol promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; CYP3A4 protein inhibits the reaction [Rifampin results in decreased chemical synthesis of 1-hydroxymethylmidazolam]; CYP3A4 protein inhibits the reaction [Rifampin results in decreased chemical synthesis of 4-hydroxymidazolam]; CYP3A4 protein inhibits the reaction [Rifampin results in decreased hydroxylation of Midazolam]; Dexamethasone promotes the reaction [Rifampin results in increased activity of CYP3A4 protein]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Econazole promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Galactosamine inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; GW 3965 inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [Rifampin results in increased activity of CYP3A4 protein]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; lorlatinib inhibits the reaction [Rifampin results in increased activity of CYP3A4 protein]; Metformin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Metformin inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; NR1H3 mutant form inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 gene promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 protein inhibits the reaction [Thapsigargin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR3C1 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; ochratoxin A inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; ochratoxin A inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; oxiconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]]; periodate-oxidized adenosine inhibits the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; PRMT1 protein affects the reaction [[Dimethyl Sulfoxide results in increased susceptibility to Rifampin] which results in increased expression of CYP3A4 mRNA]; PRMT1 protein affects the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; PRMT1 protein affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Rifampin binds to and results in increased activity of CYP3A4 protein; Rifampin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Rifampin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 4-hydroxymidazolam]; Rifampin inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[NCOA1 protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[RXRA protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [Calcitriol results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Rifampin promotes the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; Rifampin promotes the reaction [CYP3A4 protein results in increased metabolism of Lidocaine]; Rifampin promotes the reaction [NR1I2 protein binds to CYP3A4 promoter]; Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]; Rifampin results in increased expression of and results in increased activity of CYP3A4 protein; Skatole inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Skatole inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; sodium arsenite inhibits the reaction [Rifampin results in increased expression of and results in increased activity of CYP3A4 protein]; sodium arsenite inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; sulforaphane inhibits the reaction [Rifampin results in increased expression of CYP3A4]; Tetrachlorodibenzodioxin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; Thapsigargin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; trichostatin A affects the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; trichostatin A promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA] CYP3A4 protein results in decreased susceptibility to Rifampin [Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein; Rifampin results in increased activity of CYP3A4 protein Rifampin results in increased expression of CYP3A2 mRNA; Rifampin results in increased expression of CYP3A4 mRNA
[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A23-3A1 mRNA; arsenite inhibits the reaction [Rifampin results in increased expression of and results in increased activity of CYP3A23-3A1 protein]; arsenite inhibits the reaction [Rifampin results in increased expression of CYP3A23-3A1 mRNA]; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to CYP3A23-3A1 promoter]; Rifampin results in increased expression of and results in increased activity of CYP3A23-3A1 protein; sodium arsenite inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A23-3A1 mRNA]
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP7A1 mRNA [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CYP7A1 protein Rifampin results in decreased expression of CYP7A1 mRNA [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CYP7A1 protein; NR1I2 protein promotes the reaction [Rifampin results in decreased expression of CYP7A1 mRNA]
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of DDIT3 mRNA; [Rifampin co-treated with Cobicistat] results in increased expression of DDIT3 mRNA 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of DDIT3 mRNA] Rifampin results in increased expression of DDIT3 mRNA; Rifampin results in increased expression of DDIT3 protein
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of EGR1 mRNA [Rifampin co-treated with NR1I2 protein] results in increased expression of EGR1 mRNA
Rifampin results in increased phosphorylation of EIF2AK3 protein Rifampin results in increased expression of EIF2AK3 mRNA; Rifampin results in increased expression of EIF2AK3 protein 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of EIF2AK3 mRNA]; 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of EIF2AK3 protein]
Rifampin results in increased expression of and results in increased phosphorylation of ERN1 protein Rifampin results in increased expression of ERN1 mRNA
Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]]; Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]]; Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form]]; Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein]]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]; Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form]; Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein]
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FASL mRNA Rifampin results in decreased expression of FASLG mRNA; Rifampin results in decreased expression of FASLG protein Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein]]; Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein]
Rifampin results in increased expression of FASN mRNA Rifampin affects the expression of FASN mRNA pimecrolimus inhibits the reaction [Rifampin results in increased expression of FASN mRNA]
[Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of FGF19 mRNA Rifampin results in increased expression of FGF19 mRNA
[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA; INS protein inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]; SGK2 mutant form affects the reaction [Rifampin affects the expression of G6PC1 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA] Rifampin results in decreased expression of G6PC1 mRNA
4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of GPT protein]; [Rifampin co-treated with Acetaminophen] results in decreased activity of GPT protein Rifampin results in increased activity of GPT protein [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPT protein; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein] [Isoniazid co-treated with Rifampin] results in increased expression of GPT protein; [Rifampin co-treated with Isoniazid] results in increased activity of GPT protein; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased expression of GPT protein]; Rifampin inhibits the reaction [Acetaminophen results in increased expression of GPT protein]
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GPX2 mRNA; [Rifampin co-treated with Cobicistat] results in increased expression of GPX2 mRNA
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]
[Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of GSTA1 mRNA; Ketoconazole inhibits the reaction [Rifampin results in increased expression of GSTA1 mRNA]
[Rifampin co-treated with Monocrotophos] results in increased expression of GSTP1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of GSTP1 protein Rifampin results in increased expression of GSTP1 mRNA; Rifampin results in increased expression of GSTP1 protein
GSTT1 gene polymorphism affects the susceptibility to [Isoniazid co-treated with Rifampin]; GSTT1 gene polymorphism results in increased susceptibility to [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide]
Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]
HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased abundance of Reactive Oxygen Species]; HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]
[Rifampin co-treated with NR1I2 protein] results in increased expression of HIF1A mRNA [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HMOX1 mRNA dorsomorphin inhibits the reaction [Rifampin results in increased expression of HMOX1 protein] Rifampin results in increased expression of HMOX1 mRNA; Rifampin results in increased expression of HMOX1 protein [arsenite co-treated with Rifampin] results in increased expression of HMOX1 mRNA
[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of HNF4A mRNA; [Rifampin results in increased activity of NR1I2 protein] inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]; allyl isothiocyanate inhibits the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; NCOA6 promotes the reaction [Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]]; NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; Rifampin inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [MED1 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA1 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA2 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA6 protein binds to HNF4A protein]; Rifampin promotes the reaction [NR1I2 protein binds to HNF4A protein]; Rifampin promotes the reaction [PPARGC1A protein binds to HNF4A protein]
ATF4 mutant form inhibits the reaction [Rifampin results in increased expression of HSPA5 protein] [Rifampin co-treated with Cobicistat] results in increased expression of HSPA5 mRNA 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of HSPA5 mRNA]; 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of HSPA5 protein] Rifampin results in increased expression of HSPA5 mRNA; Rifampin results in increased expression of HSPA5 protein
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL1B mRNA; Rifampin inhibits the reaction [Rotenone results in increased expression of and results in increased secretion of IL1B protein]; Rifampin inhibits the reaction [Rotenone results in increased expression of IL1B mRNA] Chloroquine inhibits the reaction [Rifampin inhibits the reaction [Rotenone results in increased expression of IL1B mRNA]]; Rifampin inhibits the reaction [Rotenone results in increased expression of IL1B mRNA] Rifampin results in decreased expression of IL1B mRNA; Rifampin results in decreased expression of IL1B protein
Rifampin results in decreased expression of IL6 protein Chloroquine inhibits the reaction [Rifampin inhibits the reaction [Rotenone results in increased expression of IL6 mRNA]]; Rifampin inhibits the reaction [Rotenone results in increased expression of IL6 mRNA] Rifampin results in increased expression of IL6 protein [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of IL6 mRNA
INS protein inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA] Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA protein]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB protein]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPD mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA alternative form]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG protein]
Rifampin results in decreased metabolism of MAP1LC3B protein ATP6V0D1 protein affects the reaction [Rifampin inhibits the reaction [Rotenone results in increased lipidation of MAP1LC3B protein]]; Chloroquine promotes the reaction [Rifampin results in increased lipidation of MAP1LC3B protein]; Rifampin inhibits the reaction [Rotenone results in increased lipidation of MAP1LC3B protein]
Chloroquine inhibits the reaction [Rifampin inhibits the reaction [Rotenone results in increased phosphorylation of MAPK8 protein]]; Rifampin inhibits the reaction [Rotenone results in increased phosphorylation of MAPK8 protein]
[Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of MCL1 protein
Rifampin promotes the reaction [MED1 protein binds to and results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [MED1 protein binds to HNF4A protein] Rifampin results in decreased expression of MED1 mRNA
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC gene mutant form] results in increased expression of MKI67 protein
Camptothecin inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; Itraconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Miconazole promotes the reaction [Rifampin results in increased expression of NCOA1 mRNA]; NCOA1 protein inhibits the reaction [[NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA]; NCOA1 protein inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA]; oxiconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; pazopanib inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; pimecrolimus inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; Rifampin inhibits the reaction [NCOA1 protein binds to SLC22A1 promoter]; Rifampin inhibits the reaction [oxiconazole promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Rifampin promotes the reaction [[NCOA1 protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[NR1I2 protein binds to NCOA1 protein] which binds to CYP27A1 gene]; Rifampin promotes the reaction [NCOA1 protein binds to and results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [NCOA1 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]; Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]
NCOA6 promotes the reaction [Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [NCOA6 protein binds to HNF4A protein]
[NR1I2 protein binds to NCOR2 protein] inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Rifampin inhibits the reaction [NCOR2 protein binds to and results in decreased activity of NR1I2 protein]; Rifampin inhibits the reaction [NCOR2 protein binds to NR1I2 protein]; Rifampin inhibits the reaction [NR1I2 protein binds to NCOR2 protein]; Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]; Rifampin promotes the reaction [NR1I2 protein binds to NCOR2 protein]
Rifampin results in increased expression of NFE2L2 protein [tanshinone co-treated with Rifampin] results in increased expression of NFE2L2 mRNA; tanshinone inhibits the reaction [Rifampin results in decreased expression of NFE2L2 mRNA]; tanshinone inhibits the reaction [Rifampin results in decreased expression of NFE2L2 protein] Rifampin results in decreased expression of NFE2L2 mRNA; Rifampin results in decreased expression of NFE2L2 protein Rifampin inhibits the reaction [arsenite results in increased activity of NFE2L2 protein] Rifampin results in decreased activity of NFE2L2 protein
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of NOS2 mRNA Rifampin results in increased expression of NOS2 mRNA
NR1I2 protein affects the susceptibility to Rifampin Rifampin affects the localization of NR1I2 protein Rifampin results in decreased acetylation of NR1I2 protein NR1I2 protein results in increased susceptibility to Rifampin [Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein; Rifampin results in increased activity of NR1I2 protein NR1I2 protein mutant form results in decreased susceptibility to Rifampin 1,5-benzothiazepine analog promotes the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; 7-acetoxy-6,7-dihydro-6-(4-methoxyphenyl)pyrrolo(2,1-d)(1,5)benzothiazepine inhibits the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; [[Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein] which results in increased metabolism of and results in increased activity of and results in increased susceptibility to Cobicistat; [fexofenadine co-treated with Rifampin] results in increased activity of NR1I2 protein; [Ketoconazole co-treated with Rifampin] results in increased activity of NR1I2 protein; [Loperamide co-treated with Rifampin] results in increased activity of NR1I2 protein; [NR1I2 protein binds to NCOR2 protein] inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; [NR1I2 protein co-treated with Rifampin] results in decreased expression of CYP3A4 mRNA; [NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA; [NR1I2 protein co-treated with Rifampin] results in decreased expression of SULT1E1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein; [NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin; [Rifampin binds to and results in increased activity of NR1I2 protein] promotes the reaction [ABCB1 protein results in decreased uptake of Doxorubicin]; [Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of FGF19 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of NR1I2 protein; [Rifampin co-treated with NR1I2 protein] results in decreased expression of CYP8B1 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of FOXA1 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of GATA5 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of HDAC5 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of HNF4A mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of SERPINA4 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of STAT5A mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of ANGPTL4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of AQP3 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of BHLHE40 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of BMP4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CCN1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CCR6 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CCR7 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CDKN2B mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP26A1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP2B6 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP2S1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EDN1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EGR1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EGR2 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EGR4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EPAS1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of HBEGF mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of HEY1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of HIF1A mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP3 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of JUN mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of KLF2 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of KLF5 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of KLF6 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of LEFTY1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of MAFF mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of NPAS1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of NPPB mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of PIP4K2A mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB8 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB9 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINE1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SGK2 protein; [Rifampin co-treated with NR1I2 protein] results in increased expression of SMAD9 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SOCS3 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of UGT1A1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of VEGFD mRNA; [Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein; [Rifampin results in increased activity of NR1I2 protein] inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 protein; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCC3 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP2B6 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of DHCR24 mRNA; [Rifampin results in increased expression of NR1I2 protein] which results in increased expression of and results in increased activity of CYP3A4 protein; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; Camptothecin inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; Camptothecin inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; caraway oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Clove Oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; coriander oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]]]; Doxorubicin inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; enilconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; Epirubicin inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; Fluconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; hydroxyitraconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; INS protein inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]; Itraconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Itraconazole promotes the reaction [Rifampin results in increased expression of NR1I2 mRNA]; jasmine oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]]; Ketoconazole inhibits the reaction [Rifampin binds to and results in increased activity of NR1I2 protein]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; lemongrass oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Miconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; NCOA1 protein inhibits the reaction [[NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA]; NCOA1 protein inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA]; NCOA6 promotes the reaction [Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]]; NR1I2 gene promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 gene promotes the reaction [Rifampin results in increased metabolism of amprenavir]; NR1I2 gene promotes the reaction [Rifampin results in increased metabolism of Midazolam]; NR1I2 gene promotes the reaction [Rifampin results in increased metabolism of Nelfinavir]; NR1I2 gene promotes the reaction [Rifampin results in increased metabolism of Saquinavir]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of and results in increased activity of CYP2B6 protein]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP2C9 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 protein inhibits the reaction [[Rifampin co-treated with Benzo(a)pyrene] results in increased expression of AHR mRNA]; NR1I2 protein inhibits the reaction [Thapsigargin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in decreased expression of CYP7A1 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in decreased expression of GCK protein]; NR1I2 protein promotes the reaction [Rifampin results in decreased expression of SLC2A2 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased abundance of Lipids]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CES2 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP24A1 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of GADD45B mRNA]; ochratoxin A inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; Oils, Volatile inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Oils, Volatile promotes the reaction [Rifampin results in increased expression of NR1I2 mRNA]; oxiconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]]; oxiconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; oxiconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; pazopanib inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; pazopanib inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; pimecrolimus inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; pimecrolimus inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; PK 11195 inhibits the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; Rifampin binds to and results in increased activity of NR1I2 protein; Rifampin inhibits the reaction [NCOR1 protein binds to and results in decreased activity of NR1I2 protein]; Rifampin inhibits the reaction [NCOR2 protein binds to and results in decreased activity of NR1I2 protein]; Rifampin inhibits the reaction [NCOR2 protein binds to NR1I2 protein]; Rifampin inhibits the reaction [NR1I2 protein binds to NCOR2 protein]; Rifampin inhibits the reaction [oxiconazole promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Rifampin inhibits the reaction [oxiconazole results in increased expression of NR1I2 mRNA]; Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]; Rifampin inhibits the reaction [trichostatin A results in increased acetylation of NR1I2 protein]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[NCOA1 protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[NR1I2 protein binds to NCOA1 protein] which binds to CYP27A1 gene]; Rifampin promotes the reaction [[RXRA protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [MED1 protein binds to and results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [NCOA1 protein binds to and results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]; Rifampin promotes the reaction [NR1I2 protein binds to ABCB1 promoter]; Rifampin promotes the reaction [NR1I2 protein binds to CYP24A1 promoter]; Rifampin promotes the reaction [NR1I2 protein binds to CYP2A6 promoter]; Rifampin promotes the reaction [NR1I2 protein binds to CYP3A4 promoter]; Rifampin promotes the reaction [NR1I2 protein binds to HNF4A protein]; Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]; Rifampin promotes the reaction [NR1I2 protein binds to NCOR2 protein]; Rifampin promotes the reaction [NR1I2 protein binds to SGK2 promoter]; Rifampin promotes the reaction [NR1I2 protein results in decreased expression of SLC22A1 mRNA]; Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA]; sodium arsenite inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; sulforaphane inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; trichostatin A affects the reaction [Rifampin affects the localization of NR1I2 protein]; triptolide inhibits the reaction [Rifampin results in increased activity of NR1I2 protein] Rifampin results in increased expression of NR1I2 mRNA; Rifampin results in increased expression of NR1I2 protein Rifampin results in increased localization of NR1I2 protein [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A23-3A1 mRNA; [Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; arsenite inhibits the reaction [Rifampin results in increased localization of NR1I2 protein]; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to CYP3A23-3A1 promoter]; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]; sodium arsenite inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A23-3A1 mRNA] Rifampin binds to NR1I2 gene mutant form [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP1A2 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP2E1 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2B10 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2C protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP3A11 protein; [Rifampin binds to NR1I2 gene mutant form] which results in increased expression of CES2A mRNA; [Rifampin binds to NR1I2 gene mutant form] which results in increased expression of CYP3A11 mRNA; [Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; NR1I2 affects the reaction [Rifampin results in increased activity of CYP3A4 protein]; Rifampin affects the localization of and results in increased activity of NR1I2 protein; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter] [Rifampin binds to NR1I2 protein] which binds to CYP2C8 promoter; Rifampin binds to NR1I2 protein
Rifampin results in increased expression of NR1I3 mRNA [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP1A2 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP2E1 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2B10 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2C protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP3A11 protein Rifampin results in increased expression of NR1I3 mRNA; Rifampin results in increased expression of NR1I3 protein [NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin; [Rifampin co-treated with Monocrotophos] results in increased expression of NR1I3 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of NR1I3 protein
Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]]]; NR3C1 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA] Rifampin results in increased expression of NR3C1 mRNA
Rifampin inhibits the reaction [[Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of PARP1 protein]
[Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA] Rifampin results in increased expression of PCK1 mRNA
Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]
[Rifampin co-treated with PPARA protein co-treated with RXRA protein] results in decreased expression of UGDH mRNA [Isoniazid co-treated with Rifampin] results in decreased expression of PPARA protein
[Isoniazid co-treated with Rifampin] results in decreased expression of PPARG protein; [Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of PPARG mRNA; [Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of PPARG mRNA alternative form; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA alternative form]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG protein]; Rifampin results in increased expression of and affects the localization of PPARG protein Rifampin results in increased expression of PPARG mRNA
[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; allyl isothiocyanate inhibits the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [PPARGC1A protein binds to CYP2A6 promoter]; Rifampin promotes the reaction [PPARGC1A protein binds to HNF4A protein]
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC gene mutant form] results in increased expression of MKI67 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CCND1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CHEK2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP1B1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP2A5 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP2B9 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP4A10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP4A14 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP7A1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of DNAJA1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of EGR1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FASL mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO4 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPD1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPE1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL18 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL1B mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of RAD50 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of TNFSF10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of TRADD mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of XRCC4 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of ANXA5 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BAX mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BCL2L1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CCNG1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CXCL10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP2B10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP3A11 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP3A4 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of DDIT3 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of E2F1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GADD45A mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GPX2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM1 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM3 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HMOX1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA1L mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA8 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPB1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of IL6 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of MDM2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of NOS2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of SERPINE1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of UNG mRNA; PRKDC gene mutant form results in increased susceptibility to [Rifampin co-treated with Phenytoin co-treated with Monocrotaline]
PRMT1 protein affects the reaction [[Dimethyl Sulfoxide results in increased susceptibility to Rifampin] which results in increased expression of CYP3A4 mRNA]; PRMT1 protein affects the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; PRMT1 protein affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]
1,5-benzothiazepine analog promotes the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; 7-acetoxy-6,7-dihydro-6-(4-methoxyphenyl)pyrrolo(2,1-d)(1,5)benzothiazepine inhibits the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; [Rifampin co-treated with PPARA protein co-treated with RXRA protein] results in decreased expression of UGDH mRNA; [Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein; [RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; allyl isothiocyanate inhibits the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; PK 11195 inhibits the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [[RXRA protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA] [Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to CYP3A23-3A1 promoter]; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter] [Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of SERPINE1 mRNA [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINE1 mRNA
[Rifampin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SGK2 protein; Rifampin promotes the reaction [NR1I2 protein binds to SGK2 promoter]; SGK2 mutant form affects the reaction [Rifampin affects the expression of G6PC1 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA] Rifampin results in increased expression of SGK2 mRNA
Rifampin results in decreased expression of SLC10A1 mRNA Rifampin results in decreased expression of SLC10A1 protein [tanshinone co-treated with Rifampin] results in increased expression of SLC10A1 mRNA; [tanshinone co-treated with Rifampin] results in increased expression of SLC10A1 protein; tanshinone inhibits the reaction [Rifampin results in decreased expression of SLC10A1 protein] [Rifampin co-treated with Isoniazid] results in decreased expression of SLC10A1 protein [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of SLC10A1
Rifampin results in decreased expression of SLC22A1 mRNA; Rifampin results in decreased expression of SLC22A1 protein [NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA; NCOA1 protein inhibits the reaction [[NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA]; NCOA1 protein inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA]; Rifampin inhibits the reaction [NCOA1 protein binds to SLC22A1 promoter]; Rifampin promotes the reaction [NR1I2 protein results in decreased expression of SLC22A1 mRNA]
NR1I2 protein promotes the reaction [Rifampin results in decreased expression of SLC2A2 protein] Rifampin results in decreased expression of SLC2A2 mRNA; Rifampin results in decreased expression of SLC2A2 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]
Rifampin inhibits the reaction [SLCO1A4 protein results in increased uptake of Digoxin] Rifampin inhibits the reaction [SLCO1A4 protein results in increased uptake of epyrifenacil metabolite] Rifampin results in decreased activity of SLCO1A4 protein
Rifampin inhibits the reaction [SLCO1B3 protein results in increased import of cyanoginosin LR]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of epyrifenacil metabolite]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of estradiol-17 beta-glucuronide]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of fexofenadine]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of Hydroxyurea]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of Mesalamine]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of Sulfobromophthalein]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of Ursodeoxycholic Acid metabolite] Rifampin inhibits the reaction [SLCO1B2 protein results in increased uptake of epyrifenacil metabolite] Rifampin results in decreased activity of SLCO1B3 protein Rifampin results in decreased expression of SLCO1B3 mRNA
Rifampin results in decreased activity of SLCO1B1 protein [Rifampin results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Methotrexate
Rifampin results in increased expression of SLCO2B1 mRNA Rifampin results in decreased expression of SLCO2B1 mRNA; Rifampin results in decreased expression of SLCO2B1 protein Rifampin inhibits the reaction [Dextran Sulfate results in increased expression of SLCO2B1 mRNA]; Rifampin inhibits the reaction [Lipopolysaccharides results in increased expression of SLCO2B1 mRNA]; Rifampin inhibits the reaction [SLCO2B1 protein results in increased uptake of Mesalamine]; Rifampin inhibits the reaction [SLCO2B1 protein results in increased uptake of Sulfobromophthalein]
Rifampin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of SNCA protein modified form]; UBE2I affects the reaction [Rifampin results in increased sumoylation of SNCA protein]
[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; allyl isothiocyanate inhibits the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]
[NR1I2 protein co-treated with Rifampin] results in decreased expression of SULT1E1 mRNA; [Rifampin results in increased activity of NR1I2 protein] inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]; Rifampin inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]
[Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]
Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]
[Rifampin co-treated with PPARA protein co-treated with RXRA protein] results in decreased expression of UGDH mRNA Rifampin results in increased expression of UGDH mRNA
Rifampin affects the expression of UGT1A1 mRNA Rifampin results in increased expression of UGT1A1 mRNA [Rifampin co-treated with NR1I2 protein] results in increased expression of UGT1A1 mRNA; [Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of UGT1A1 mRNA
CD28 protein affects the reaction [Gold Sodium Thiomalate results in decreased activity of FBL protein] CD28 protein affects the susceptibility to Gold Sodium Thiomalate
Gold Sodium Thiomalate affects the localization of FBL protein Gold Sodium Thiomalate results in decreased activity of FBL protein CD28 protein affects the reaction [Gold Sodium Thiomalate results in decreased activity of FBL protein]; IFNG protein affects the reaction [Gold Sodium Thiomalate results in decreased activity of FBL protein]; IL4 protein affects the reaction [Gold Sodium Thiomalate results in decreased activity of FBL protein]; IL6 protein affects the reaction [Gold Sodium Thiomalate results in decreased activity of FBL protein]
IFNG protein affects the reaction [Gold Sodium Thiomalate results in decreased activity of FBL protein] IFNG protein affects the susceptibility to Gold Sodium Thiomalate
Gold Sodium Thiomalate inhibits the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Gold Sodium Thiomalate inhibits the reaction [IL1B protein results in increased expression of PTGES]
IL4 protein affects the reaction [Gold Sodium Thiomalate results in decreased activity of FBL protein] IL4 protein affects the susceptibility to Gold Sodium Thiomalate
[Gold Sodium Thiomalate co-treated with mercury nitrate analog] results in increased expression of IL6 protein Gold Sodium Thiomalate results in decreased expression of IL6 mRNA; Gold Sodium Thiomalate results in decreased expression of IL6 protein IL6 protein affects the susceptibility to Gold Sodium Thiomalate IL6 protein affects the reaction [Gold Sodium Thiomalate results in decreased activity of FBL protein]
Gold Sodium Thiomalate inhibits the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]
Gold Sodium Thiomalate inhibits the reaction [TXNRD1 protein affects the metabolism of Dithionitrobenzoic Acid] Gold Sodium Thiomalate results in decreased activity of TXNRD1 protein
Stavudine results in decreased expression of ADIPOQ protein Stavudine results in decreased expression of ADIPOQ mRNA; Stavudine results in decreased expression of ADIPOQ protein
[Stavudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of FASN mRNA; [Stavudine co-treated with Lamivudine] results in increased expression of FASN mRNA Stavudine results in decreased expression of FASN protein
[Stavudine co-treated with Lamivudine co-treated with Indinavir] affects the expression of LPL mRNA; [Stavudine co-treated with Lamivudine co-treated with Nelfinavir] results in decreased expression of LPL mRNA; [Stavudine co-treated with Lamivudine] affects the expression of LPL mRNA
[Stavudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ME1 mRNA; [Stavudine co-treated with Lamivudine co-treated with Nelfinavir] results in decreased expression of ME1 mRNA; [Stavudine co-treated with Lamivudine] results in increased expression of ME1 mRNA Stavudine results in increased expression of ME1 mRNA
Stavudine results in decreased expression of PPARG mRNA Stavudine results in decreased expression of PPARG mRNA; Stavudine results in decreased expression of PPARG protein
browse the term
